SEARCH

Search Details

TAKEMORI Toshiyuki
University Hospital / Department of Rehabilitation
Assistant Professor

Researcher basic information

■ Research Areas
  • Life sciences / Tumor biology
  • Life sciences / Orthopedics

Research activity information

■ Award
  • Jul. 2025 第464回整形外科集談会京阪神地方会, Best Paper Award, 悪性腫瘍切除後の脛骨広範骨欠損に対する新たな生物学的骨再建法：チタンメッシュプレートと自家細片化腸骨移植を用いた一例
    永家智志, 深瀬直政, 竹森俊幸, 原仁美, 黒田良祐, 秋末敏宏

  • 2025 JOS Best Paper Award, Comparison of clinical outcome between surgical treatment and particle beam therapy for pelvic bone sarcomas: A retrospective multicenter study in Japan.
    Takemori T., Hara H., Kawamoto T., Fukase N., Sawada R., Fujiwara S., Fujita I., Fujimoto T., Morishita M., Yahiro S., Miyamoto T., Saito M., Sugaya J., Hayashi K., Kawashima H., Torigoe T., Nakamura T., Kondo H., Wakamatsu T., Watanuki M., Kito M., Tsukushi S., Nagano A., Outani H., Toki S., Nishimura S., Kobayashi H., Watanabe I., Demizu Y., Sasaki R., Fukumoto T., Matsumoto T., Kuroda R., Akisue T.

  • Oct. 2021 第36回日本整形外科学会基礎学術集会, 優秀演題賞（ポスター）, 乳癌骨転移による骨破壊に寄与するmiRNAの検討
    北山和道, 河本旭哉, 原仁美, 川上洋平, 竹森俊幸, 藤原周一, 八尋俊輔, 宮本智弘, 黒田良祐, 秋末敏宏

■ Paper
  • Toshiyuki Takemori, Hitomi Hara, Keisuke Oe, Naomasa Fukase, Ryoko Sawada, Yuta Nakamatsu, Shotaro Nakamura, Tomoaki Fukui, Yohei Kumabe, Kenichi Sawauchi, Ryosuke Kuroda, Toshihiro Akisue
    BACKGROUND/AIM: Periprosthetic joint infection (PJI) after tumor endoprosthetic reconstruction is a devastating complication associated with substantial morbidity. Infection rates are considerably higher than those reported after conventional arthroplasty, and implant removal often leads to major functional impairment, complex revision surgery, or even amputation. Therefore, treatment strategies that achieve infection control while preserving the implant are critically important in this patient population. Continuous local antibiotic perfusion (CLAP) is a recently introduced technique that enables sustained delivery of high local antibiotic concentrations directly to the infected site. However, its role in managing PJI after tumor endoprosthetic reconstruction remains unclear. CASE REPORT: We conducted a retrospective case series of three patients with PJI after tumor endoprosthetic reconstruction who were treated with CLAP at our institution. All patients underwent surgical debridement followed by placement of local perfusion tubes for continuous antibiotic delivery combined with systemic antibiotic therapy. Clinical characteristics, treatment details, complications, and infection-related outcomes were evaluated. All three patients successfully completed a 14-day course of CLAP. Infection control was achieved without implant removal in all cases. No major CLAP-related complications occurred during a follow-up ranging from 2 to 22 months. One patient required two sequential CLAP procedures to achieve infection control. Systemic toxicity related to local antibiotic administration was not observed, except for a transient increase in serum gentamicin levels in one case, which normalized after dose adjustment. CONCLUSION: In this small case series, CLAP enabled infection control with implant retention in patients with PJI after tumor endoprosthetic reconstruction. Given the high morbidity associated with these infections and the importance of limb preservation and continuation of oncologic therapy, CLAP may represent a promising implant-preserving treatment strategy in this challenging clinical setting.
    Lead, Aug. 2026, Anticancer research, 46(8) (8), 4573 - 4581, English, International magazine
    Scientific journal

  • Yu Toda, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Eisuke Kobayashi, Toshiyuki Takemori, Hiroya Kondo, Shudai Muramatsu, Takahiro Higashi, Akira Kawai
    BACKGROUND: Ewing sarcoma arises at both skeletal (SES) and extraskeletal (EES) sites; however, whether the anatomical origin influences outcomes in current practice remains uncertain. This study compared clinical characteristics, treatment, and survival rates of patients with SES and EES in a large nationwide Japanese cohort. METHODS: We analyzed patients diagnosed with Ewing's sarcoma between 2016 and 2019 in Japan, classified as having SES or EES, using a population-based cancer registry. Demographics, stage, treatment, hospital characteristics, and overall survival (OAS) were evaluated using chi-square tests, Kaplan-Meier estimates, and log-rank analyses. RESULTS: We identified 505 patients with ES: 211 with SES and 294 with EES. Patients with EES were significantly older than those with SES (P < .001). Chemotherapy (97.7% vs. 74.9%, P < .001) and radiotherapy (36.6% vs. 27.1%, P = .024) were administered more frequently in the SES group. Three-year OAS rate was 62.3%, 73.5% for SES, and 54.7% for EES, with significantly worse survival in EES group (P < .001). Favorable prognostic factors included younger age, localized stage, surgery, chemotherapy, treatment at certified institutions, higher hospital volume, and female sex among patients with EES. CONCLUSIONS: In this nationwide cohort, EES presented at older ages, received less chemotherapy, and demonstrated inferior survival compared to SES, despite a similar stage distribution. Patient background, hospital type, and volume influenced the outcomes. These findings underscore the need for equitable multimodal therapy delivery, particularly for patients with EES.
    May 2026, Japanese journal of clinical oncology, English, International magazine
    Scientific journal

  • Hiroya Kondo, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai
    We analyzed survival rates and prognostic factors for renal sarcoma using Japan's National Cancer Registry data. We conducted a retrospective cohort study of patients diagnosed with renal sarcoma (2016-2019). Prognostic factors were evaluated using Cox regression analyses. Among 235 patients, female sex (HR, 0.43; 95% CI, 0.23-0.83; p = 0.012), older age (≥60 years: HR, 5.87; p < 0.001), histologic subtype (angiosarcoma: HR, 12.65; p < 0.001), and distant disease (HR, 6.32; p < 0.001) were significant independent prognostic factors. Surgical resection (HR, 0.41; p = 0.004) and radiation therapy (HR, 0.39; p = 0.010) were associated with improved survival. Histologic subtype is the most critical prognostic factor for renal sarcoma in Japan's aging population, with dramatic survival differences: clear cell sarcoma (94.4% 3-year survival) versus angiosarcoma (19.0%). This heterogeneity mandates histology-specific treatment protocols rather than organ-based approaches, with particular relevance for aging societies in Asia.
    Mar. 2026, Cancer investigation, 1 - 10, English, International magazine
    Scientific journal

  • Hiroya Kondo, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai
    BACKGROUND: Liposarcoma demonstrates significant biological and clinical heterogeneity across subtypes, yet optimal treatment strategies remain controversial. We evaluated subtype-specific treatment outcomes and hospital volume effects using population-based registry data. METHODS: We conducted a population-based cohort study analyzing 6,678 patients with liposarcoma diagnosed between 2016 and 2019 from the Japanese National Cancer Registry. Subtype-specific clinical characteristics, treatment patterns, and survival outcomes were evaluated using Cox regression and Kaplan-Meier methods. Propensity score matching was performed to assess radiotherapy and chemotherapy effectiveness while controlling for confounding variables. RESULTS: Well-differentiated liposarcoma was most common (46.2 %), followed by dedifferentiated (27.8 %), myxoid (10.8 %), and pleomorphic (3.2 %) subtypes. Myxoid liposarcomas predominantly affected patients aged <60 years (63.8 %). Multivariate analysis identified male sex (HR 1.264, p = 0.008), older age (HR 3.307, p < 0.001), retroperitoneal location (HR 1.861, p < 0.001), distant disease (HR 6.091, p < 0.001), and treatment at low-volume hospitals (HR 1.381, p = 0.001) as independent poor prognostic factors. Propensity score-matched analysis demonstrated improved survival with radiotherapy in dedifferentiated liposarcomas (3-year survival: 76.5 % vs. 66.1 %, p = 0.022) and with chemotherapy in pleomorphic liposarcomas (3-year survival: 87.5 % vs. 68.8 %, p = 0.038). CONCLUSIONS: Treatment efficacy varies significantly across liposarcoma subtypes, with potential survival benefits of radiotherapy in dedifferentiated subtypes and chemotherapy in pleomorphic subtypes. These findings support subtype-guided treatment approaches and suggest benefits of centralized care for optimal therapy implementation.
    Jan. 2026, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, English, Domestic magazine
    Scientific journal

  • Satoshi Kamio, Koichi Ogura, Yoshiyuki Suehara, Rina Kitada, Masachika Ikegami, Kuniko Sunami, Takafumi Koyama, Noboru Yamamoto, Seiji Shimomura, Hiroya Kondo, Toshiyuki Takemori, Shuhei Osaki, Eisuke Kobayashi, Shintaro Iwata, Shinji Kohsaka, Akira Kawai
    BACKGROUND: Ewing sarcoma (ES) is a malignant type of bone and soft tissue tumor with EWSR1-ETS gene fusions as the primary driver alteration. Incidence is higher in White populations compared to Black and Asian populations. Researchers use next-generation sequencing to identify alterations as potential therapeutic targets. We compared the data from the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets in the USA with the data from Center for Cancer Genomics and Advanced Therapeutics in Japan. METHODS: We sequenced tumor DNA from 81 ES samples using the FoundationOne® CDx for multigene panel testing. Genetic alterations were interpreted via the Cancer Knowledge Database (CKDB) and potentially actionable alterations were classified into levels A-F. RESULTS: Analysis of 81 ES samples revealed 556 mutations in 197 genes and 126 copy-number alterations in 58 genes. Potentially actionable alterations were detected in 10 patients (12.3%) at CKDB levels A or C. STAG2 mutations accounted for 3.7%, TP53 mutations for 17.3%, and CDKN2A deletions for 13.6%. There was no significant difference in overall survival after genomic profiling test enrollment for STAG2 and TP53 mutations (P = .663 and P = .767), but those with CDKN2A and CDKN2B deletions had poor prognosis (P = .024 and P = .012). CONCLUSION: Compared to previous reports, Japanese ES cases showed lower STAG2 and higher TP53 mutation frequencies. CDKN2A and CDKN2B deletions may serve as prognostic biomarkers indicating unfavorable outcomes.
    Nov. 2025, Japanese journal of clinical oncology, English, International magazine
    Scientific journal

  • Shudai Muramatsu, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Eisuke Kobayashi, Takahiro Higashi, Yu Toda, Toshiyuki Takemori, Hiroya Kondo, Akira Kawai
    BACKGROUND: The national epidemiology of malignant peripheral nerve sheath tumor (MPNST) remains underexplored. We analyzed Japanese domestic statistics for MPNST using the National Cancer Registry (NCR), a population-based database launched in 2016. METHODS: We analyzed 837 MPNST cases diagnosed between 2016 and 2019, comparing them with 22,685 non-MPNST soft tissue sarcomas. We assessed demographics, treatment, and survival using Kaplan-Meier and Cox proportional hazards models. RESULTS: The age-adjusted incidence of MPNST in Japan was 0.13 per 100,000. Unlike other sarcomas, MPNST showed a balanced sex ratio and a relatively higher proportion of adolescent and young adult (AYA) patients (18.5 % vs. 10.7 %, p < 0.001). Most MPNSTs (87.4 %) originated from the skin and soft tissues. The 3-year survival rate for MPNST patients (53.0 %) was lower than that for other sarcomas (64.3 %, p < 0.001). Surgery was associated with longer survival (hazard ratio [HR]: 2.09; p < 0.001), while no clear benefit was observed for chemotherapy or radiotherapy. Radiotherapy was more frequently used in MPNST patients (21.1 % vs. 15.6 %, p < 0.001), likely reflecting a selection bias towards non-surgical cases. CONCLUSIONS: This is the first study to analyze the national epidemiology and prognosis of MPNST in a socio-economically homogeneous, single ethnic group. MPNST primarily affected the skin and soft tissues, with a higher incidence in the AYA group. Surgery was associated with better outcomes, whereas chemotherapy and radiotherapy implied poorer prognosis owing to selection bias for unresectable cases. The NCR provides a valuable model for research on rare diseases in homogeneous populations.
    Oct. 2025, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, English, Domestic magazine
    Scientific journal

  • Shuichi Fujiwara, Ikuo Fujita, Toshiyuki Takemori, Takuya Fujimoto, Shunsuke Yahiro, Ami Sawada, Ryosuke Kuroda
    Melorheostosis, also known as Leri's disease, is a rare sclerosing bone dysplasia characterized by abnormal overgrowth of cortical bone, typically appearing as "dripping candle wax" on imaging. It most commonly affects the diaphyseal regions of the long bones in the lower limbs and may result in limb-length discrepancy, joint stiffness, progressive deformity, and soft tissue ossification. Owing to its rarity, treatment approaches are usually individualized. Here, we report the case of a 41-year-old female who presented with progressive limitation of right hip mobility since childhood, which began to interfere with daily activities. Imaging revealed extensive soft tissue ossification and endomedullary sclerosis around the right hip with cortical excrescence resembling candle wax dripping, suggesting melorheostosis. Following multidisciplinary evaluation, surgical excision of the bony mass and passive manipulation of the hip joint were performed. Histological examination confirmed a dense, compact bone resembling cortical bone. Postoperatively, hip flexion improved from 20° to 60° and abduction improved from 15° to 20°, with no evidence of joint instability. At the 30-month follow-up, mild limitation of motion persisted (flexion, 45°; abduction, 25°); however, the patient maintained good function with no significant impact on daily activities.
    Oct. 2025, Cureus, 17(10) (10), e94263, English, International magazine
    Scientific journal

  • Shuichi Fujiwara, Hitomi Hara, Naomasa Fukase, Ryoko Sawada, Toshiyuki Takemori, Tomohiro Miyamoto, Yuta Nakamatsu, Ryosuke Kuroda, Toshihiro Akisue
    Granulocyte-colony stimulating factor (G-CSF) is commonly used to reduce neutropenia-related complications following chemotherapy. It is a glycoprotein that stimulates the production of granulocytes [white blood cells (WBCs) in the bone marrow. In the present study, the case of a 59-year-old man is presented who received chemotherapy (eribulin) for liver metastases from sacral chordoma and subsequently developed acute aortitis after the administration of G-CSF. Grade 3 neutropenia occurred on day eight of the fifth chemotherapy cycle, and pegfilgrastim was administered on day nine. A total of 3 days after pegfilgrastim administration, the patient developed a fever that persisted for 6 days. He visited our hospital on day 18 with abdominal pain and elevated WBC count and C-reactive protein levels. Febrile neutropenia was suspected, and antibiotics were administered. However, both blood and urinalysis cultures returned negative results, and antibiotics were ineffective. Contrast-enhanced computed tomography revealed a thickened wall of the brachiocephalic artery and abdominal aorta, consistent with aortitis. After discontinuing the antibiotics, the patient was monitored closely without further treatment. His condition improved within a few days; therefore, it was concluded that aortitis was induced by G-CSF.
    Oct. 2025, Biomedical reports, 23(4) (4), 161 - 161, English, International magazine
    Scientific journal

  • Seiji Shimomura, Koichi Ogura, Toshiyuki Takemori, Takeichiro Kimura, Akihiko Yoshida, Akira Kawai
    Sep. 2025, INTERNATIONAL CANCER CONFERENCE JOURNAL, English
    Scientific journal

  • Toshiyuki Takemori, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Hiroya Kondo, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai
    BACKGROUND: Retroperitoneal sarcoma (RPS) is a rare cancer, so few reports have previously characterized its national profiles. The capture rate of RPS in the Bone and Soft Tissue Tumor Registry was only 20%. The present study aimed to clarify the characteristics and clinical outcomes of RPS using the National Cancer Registry (NCR), which contains nationwide population-based data from Japan. METHODS: We analyzed data from 20,079 patients with soft-tissue sarcomas (STS), entered into the NCR in 2016-2019 using the International Classification of Diseases-Oncology, Third Edition cancer topography and morphology codes. We extracted demographics (sex, age), tumor details (tumor location, histology, extent of disease), treatment, and prognosis for each patient. RESULTS: Of the 20,079 patients, 3311 patients were diagnosed with RPS. RPS accounts for 16.5% of all STS, with an adjusted incidence of 0.41/100,000/year. Of patients with RPS, 70.9% were aged 60 years or older and 52.7% were at the 'regional' stage at the time of diagnosis. Surgery was performed in 70.0% of cases, while chemotherapy and radiotherapy were performed in only 21.5% and 8.3% of cases, respectively. The 3-year overall survival (OAS) of the RPS patients was 57.3%. The multivariate analyses showed that of the 3,311 patients with RPS, worse OAS was associated with being male, older age, a histology of undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma, cancer discovery other than by cancer/health screening, being treated at low-volume hospitals, advanced disease, and not having surgery. CONCLUSIONS: The present study is the first to have clarified the epidemiology, clinical features, treatment, prognosis, and significant factors affecting prognosis of patients with RPS in Japan. LEVEL OF EVIDENCE: Level Ⅲ, prognostic studies.
    Lead, Sep. 2025, Journal of surgical oncology, English, International magazine
    Scientific journal

  • Toshiyuki Takemori, Eisuke Kobayashi, Shudai Muramatsu, Shintaro Iwata, Koichi Ogura, Shuhei Osaki, Suguru Fukushima, Seiji Shimomura, Hiroya Kondo, Satoshi Kamio, Akira Kawai
    Lead, Jul. 2025, JBJS OPEN ACCESS, 10(3) (3), English
    Scientific journal

  • Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Hiroya Kondo, Eisuke Kobayashi, Ayumu Arakawa, Chitose Ogawa, Yoko Katoh, Takahiro Higashi, Akira Kawai
    BACKGROUND: No previous reports have characterized national profiles of osteosarcoma. In this study, we examined nationwide statistics for osteosarcoma in Japan using data from the National Cancer Registry (NCR), a population-based cancer registry launched in 2016. METHODS: We identified 1187 patients with osteosarcomas entered in the NCR during 2016-2019 using the cancer topography and morphology codes from the International Classification of Diseases for Oncology, Third Edition. We extracted data on patient demographics (sex, age), tumor details (reason for diagnosis, tumor location, extent of disease), hospital volume and facility type, treatment, and prognosis for each patient. RESULTS: Osteosarcoma showed a slight male preponderance. Although osteosarcoma associated with Paget's disease of bone was extremely rare (0.2%), the age distribution had two peaks: in the second and the seventh to eighth decades of life, suggesting the bimodal age peaks in Japan result from the increasing proportion of the elderly population. Elderly osteosarcoma cases more commonly involved the axial skeleton including the craniofacial bones, pelvis, and spine and showed a lower frequency of localized disease at presentation. Furthermore, elderly patients were less likely to undergo intensive treatment involving chemotherapy and surgery, possibly leading to poorer survival outcomes associated with advanced age. CONCLUSIONS: This is the first study to analyze NCR data and provides an overview of the epidemiology, clinical features, treatment, prognosis, and significant factors affecting prognosis of patients with osteosarcoma in Japan. We must document our data regarding elderly patients' outcomes so other countries showing similar population aging trends can learn from our experiences. LEVEL OF EVIDENCE: Prognostic studies, Level III.
    Jun. 2025, Japanese journal of clinical oncology, English, International magazine
    Scientific journal

  • Toshiyuki Takemori, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Hiroya Kondo, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai
    Angiosarcoma is so rare, no reports on its epidemiology and prognosis using nationwide population-based data exist. The present study aimed to clarify the characteristics and clinical outcomes of angiosarcoma using the National Cancer Registry (NCR) in Japan. We analyzed data from 23,522 patients with soft-tissue sarcomas (STS), entered in the NCR in 2016-2019 using the International Classification of Diseases-Oncology, Third Edition cancer topography and morphology codes. We extracted demographics, tumor details, treatment, and prognosis for each patient. Of 23,522 STS patients, 1,973 patients were enrolled in the angiosarcoma group and 21,549 in the non-angiosarcoma group. Angiosarcoma accounts for 8.4% of all STS (adjusted incidence: 0.18/100,000/year). Most angiosarcoma patients were men (58.7%) and the most common tumor location was the head/neck (51.0%). In the angiosarcoma group (compared to the non-angiosarcoma group): age at diagnosis was significantly older; more tumors were localized; chemotherapy and radiotherapy were more common; surgery was less common; and the overall survival was significantly worse (P < 0.001). Several factors were associated with worse overall survival in the multivariate analyses. The present study is the first to have clarified the epidemiology, clinical features, treatment, prognosis, and significant factors affecting prognosis of patients with angiosarcoma in Japan.
    Lead, Mar. 2025, Scientific reports, 15(1) (1), 9960 - 9960, English, International magazine
    Scientific journal

  • Yu Toda, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Eisuke Kobayashi, Toshiyuki Takemori, Hiroya Kondo, Shudai Muramatsu, Takahiro Higashi, Akira Kawai
    BACKGROUND: In aging societies like Japan, the number of elderly bone sarcoma (BS) and soft-tissue sarcoma (STS) patients is increasing. However, these malignancies' behavior is incompletely understood. We investigated clinical features, treatment modalities, survival, and prognostic factors for elderly BS and STS patients using Japan's National Cancer Registry (NCR). METHODS: We identified data for 11,015 individuals ≥ 70 diagnosed with BS or STS in 2016-2019 by ICD-O-3 cancer topography and morphology codes and analyzed patient characteristics, disease information, initial diagnostic process, treatment, and prognosis. RESULTS: We analyzed 1072 BS cases and 9933 STS cases. There was no significant sex difference among BS or STS. The most common histological subtypes were chondrosarcoma (N = 310, 29%) and liposarcoma (N = 1533, 15%). Twelve percent of BS and 11% of STS patients had distant metastasis at first presentation. Forty-six percent of BS and 50% of STS patients underwent surgery. The number of patients > 80 who underwent surgery or had chemotherapy was significantly smaller than patients 70-79 (P < 0.001; P < 0.001). Three-year overall survival (OAS) was 46% among BS and 50% among STS patients. Adjusted analyses provided significant associations between OAS and age, histological subtype, treatment, and extent of disease in BS, and age, sex, histological subtype, tumor location, treatment, and extent of disease in STS. CONCLUSIONS: This study featured elderly BS and STS patients, presenting epidemiology, clinical characteristics, treatment, and oncological outcomes based on the NCR. It gives clinicians valuable information to develop treatments for elderly BS and STS patients for future aging societies.
    Feb. 2025, International journal of clinical oncology, English, Domestic magazine
    Scientific journal

  • Shuhei Iwata, Rei Noguchi, Julia Oosaki, Yuki Adachi, Yomogi Shiota, Eisuke Kobayashi, Toshiyuki Takemori, Shogo Nishino, Akihiko Yoshida, Seiji Ohtori, Akira Kawai, Tadashi Kondo
    Solitary fibrous tumors (SFTs) are rare mesenchymal tumors characterized by recurrent NAB2::STAT6 gene fusion, which are associated with an unpredictable clinical course, including the potential for recurrence or metastasis. Current therapeutic approaches for relapsed cases remain ineffective, and there is no established standard of care for SFTs. Although patient-derived cancer cell lines are fundamental research tools, only a few cell lines have been developed for SFTs. To address this, we established a novel SFT cell line, NCC-SFT1-C1, derived from surgically resected tumor tissues of a patient with SFT. The cell line retains the characteristic recurrent NAB2::STAT6 gene fusion in concordance with the matched original tumor. These cells exhibit moderate proliferation, invasion ability, and spheroid formation. We demonstrated that NCC-SFT1-C1 cells are useful for the high-throughput screening of the antiproliferative effects of 221 oncology drugs. Therefore, the NCC-SFT1-C1 cell line is a valuable tool for basic and preclinical studies on SFT.
    Feb. 2025, Human cell, 38(2) (2), 49 - 49, English, Domestic magazine
    Scientific journal

  • Hiroya Kondo, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai
    BACKGROUND: Chondrosarcoma (CS) is a rare malignant bone tumor exhibiting diverse histological features and clinical behaviors. This study aimed to investigate the epidemiological characteristics, clinical features, prognostic factors, and subtype-specific differences of CS in Japan using National Cancer Registry data. METHODS: We analyzed data from CS cases diagnosed between 2016 and 2019, calculating age-adjusted incidence, estimating overall survival, and identifying prognostic factors through multivariate analysis. RESULTS: The study identified 1015 CS cases with an age-adjusted incidence of 0.159 per 100 000 population and a mean overall survival of 1205.2 days. Multivariate analysis revealed that female sex, younger age (15-39 years), histological subtypes other than dedifferentiated CS, localized disease, and surgical treatment were associated with better prognoses. Conversely, male sex, older age (≥75 years), dedifferentiated subtype, advanced stage, and non-surgical treatment were linked to a higher risk of death. Significant differences in sex distribution, age at diagnosis, tumor location, disease stage, and tumor differentiation were observed among CS subtypes. CONCLUSION: This comprehensive analysis provides valuable insights into CS epidemiology, prognostic factors, and subtype-specific characteristics in Japan. The identification of high-risk groups emphasizes the need for improved therapeutic strategies and supportive care. The observed heterogeneity among CS subtypes underscores the importance of individualized management approaches in treating this complex malignancy.
    Feb. 2025, Japanese journal of clinical oncology, English, International magazine
    Scientific journal

  • Tomohiro Miyamoto, Naomasa Fukase, Teruya Kawamoto, Shuichi Fujiwara, Hitomi Hara, Ryoko Sawada, Yuta Nakamatsu, Yutaka Mifune, Kenichiro Kakutani, Yuichi Hoshino, Shinya Hayashi, Tomoyuki Matsumoto, Takehiko Matsushita, Michiyo Koyanagi-Aoi, Takashi Aoi, Toshiyuki Takemori, Shunsuke Yahiro, Ryosuke Kuroda, Toshihiro Akisue
    Cancer stem cells (CSCs) have been implicated as critical mediators in the progression, chemoresistance and metastatic capabilities of diverse malignancies, including osteosarcoma (OS). The authors have succeeded in generating CSC‑like cells (MG‑OKS) from the OS cell line MG‑63 by transducing defined factors. A significant increase in small proline‑rich protein 1A (SPRR1A) expression, a cross‑linked envelope protein in keratinocytes, was observed in MG‑OKS cells. Therefore, SPRR1A could be involved in tumor initiation, growth and poor OS progression. However, its specific role in OS remains unclear. The present study aimed to evaluate the role of SPRR1A in OS both in vitro and in vivo using MG‑OKS cells. Three experimental groups were established: MG‑OKS cells transfected with SPRR1A small interfering (si)RNA (siMG‑OKS), untransfected MG‑OKS cells and MG‑OKS cells transfected with scrambled siRNA (scMG‑OKS) as controls. SPRR1A expression, morphological changes, cell proliferation and migration were assessed in these groups. RNA sequencing was performed to examine the genetic changes caused by SPRR1A suppression. To evaluate tumorigenicity in vivo, cells from each group were subcutaneously transplanted into the backs of nude mice. Tumor volume and Ki‑67 expression were assessed and compared among the three groups at four weeks post‑transplantation. The siMG‑OKS group exhibited altered cell morphology, reduced cell proliferation and decreased migratory abilities in vitro. RNA sequencing revealed suppression of genes involved in cell adhesion in the siMG‑OKS group. Furthermore, the in vivo tumorigenicity of siMG‑OKS was lower than that of the other two experimental groups. These findings suggest that SPRR1A is one of the key cell adhesion‑related molecules involved in OS progression, potentially serving as a therapeutic target for this refractory tumor. However, further research is needed to fully elucidate the mechanisms by which SPRR1A influences OS pathogenesis and to explore its clinical potential.
    Feb. 2025, Oncology reports, 53(2) (2), English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Toshiyuki Takemori, Eisuke Kobayashi, Akihiko Yoshida, Ayumu Arakawa, Hiroya Kondo, Satoshi Kamio, Seiji Shimomura, Shuhei Osaki, Koichi Ogura, Shintaro Iwata, Chitose Ogawa, Akira Kawai, Kimiteru Ito
    INTRODUCTION: We aimed to identify a new biomarker using 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) parameters to identify osteosarcoma patients with standard response after neoadjuvant chemotherapy (NAC). PATIENTS AND MATERIALS: Fifty-four patients with conventional osteosarcoma (age ≤39 years) were included in this study. All patients underwent 18F-FDG PET/CT before (PET1) and after NAC (PET2). We measured PET parameters, including maximum, average, and peak standardized uptake value (SUVmax, SUVave, and SUVpeak); metabolic tumor volume (MTV); and total lesion glycolysis (TLG). Their changes (ΔPET = PET2/PET1) were also examined. The patients were classified into 4 groups based on the histological tumor necrosis rate (TNR): G0 (<50%), G1 (50 to < 90%), G2 (90 to < 100%), and G3 (100%). G0 and G1 patients were enrolled in the standard responder (SR) group (n = 35), while G2 and G3 patients were enrolled in the good responder (GR) group (n = 19). We examined the correlation between changes in each 18F-FDG PET/CT parameter and TNR as well as overall survival (OS) and progression-free survival (PFS) among the 4 groups. In the SR group, the median value of ΔSUVmax was calculated and correlated with prognostic stratification. RESULTS: The changes in each PET parameter were correlated with TNR, with SUVpeak showing the strongest correlation. Moreover, in the SR group, there were no differences in OS or PFS between G0 and G1. Patients in the SR group were stratified into 2 groups according to the median ΔSUVmax value (0.62). Patients with ΔSUVmax < 0.62 had significantly better OS (P < 0.01) and PFS (P = 0.02) in comparison with patients with ΔSUVmax ≥ 0.62. In multivariate analyses, ΔSUVmax showed a correlation with OS in the SR group. DISCUSSION: This study revealed that ΔSUVmax may confirm the preoperative stratification of the prognosis be a predictive biomarker for patients in the SR group. Moreover, the preoperative identification of patients with a worse prognosis in the SR group has a significant impact on improving the clinical outcomes of patients with osteosarcoma. LEVEL OF EVIDENCE: Prognostic studies, Level III. See Instructions for Authors for a complete description of levels of evidence.
    Lead, 2025, JB & JS open access, 10(4) (4), English, International magazine
    Scientific journal

  • Statistics of chondrosarcoma in Japan: Report from the population-based cancer registry in Japan
    Hiroya Kondo, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai
    Jan. 2025, CANCER SCIENCE, 116, 600 - 600, English

  • Toshiyuki Takemori, Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Hiroya Kondo, Eisuke Kobayashi, Takahiro Higashi, Akira Kawai
    BACKGROUND: Clear cell sarcoma is rare, so no reports have previously characterized its national profiles. We examined the nationwide epidemiology and clinical outcomes of patients with clear cell sarcoma based on the National Cancer Registry in Japan. METHODS: Overall, 23 522 patients with soft tissue sarcoma-entered in the National Cancer Registry in 2016-2019 using the International Classification of Diseases for Oncology, Third Edition cancer topography and morphology codes-were enrolled in either the clear cell or the non-clear cell sarcoma group. Data extracted included: demographics (sex and age), tumor details (reason for diagnosis, tumor location, histology and stage), hospital volume and facility type, treatment and prognosis for each patient. RESULTS: Of 23 522 soft tissue sarcoma patients, 122 were enrolled in the clear cell sarcoma group and 23 400 in the non-clear cell sarcoma group. The incidence of clear cell sarcoma was 0.52% of all soft tissue sarcoma, with an age-adjusted incidence of 0.024/100 000/year. The age at diagnosis was significantly younger, and more tumors were at the localized stage in the clear cell than the non-clear cell sarcoma group. In addition, the overall survival in the clear cell group was worse than in the non-clear cell group (P < 0.001). Of 122 patients with clear cell sarcoma, the localized stage, surgical treatment and treatment without chemotherapy were associated with better overall survival in the univariate analyses. CONCLUSIONS: The present study is the first to have clarified the epidemiology, clinical features, treatment, prognosis and significant factors affecting the prognosis of patients with clear cell sarcoma in Japan.
    Lead, Dec. 2024, Japanese journal of clinical oncology, 54(12) (12), 1281 - 1287, English, International magazine
    Scientific journal

  • Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Hiroya Kondo, Eisuke Kobayashi, Yoko Katoh, Takahiro Higashi, Akira Kawai
    BACKGROUND: No previous reports have characterized national profiles of soft-tissue sarcoma overall. We examined the nationwide statistics for soft-tissue sarcoma in Japan using data from the population-based National Cancer Registry. METHODS: We identified 23 522 soft-tissue-sarcoma patients who were entered in the National Cancer Registry during 2016-19 using International Classification of Diseases-Oncology, Third Edition codes for cancer topography and morphology. We extracted data on patient demographics, tumor details (reason for diagnosis, tumor location, histology, extent of disease), hospital volume/type, treatment, and prognosis for each patient. RESULTS: Soft-tissue sarcoma showed a slight male preponderance. Approximately 5500-6000 new cases were diagnosed as soft-tissue sarcoma per year, with the age-adjusted incidence of soft-tissue sarcoma being 3.22/100000/year. The age distribution showed a single peak in the 70-79 age range, and sex-stratified data showed it was higher in men. The most common histologic subtype was liposarcoma. The most frequent tumor locations were the soft tissue and skin, followed by the retroperitoneum. Extent of disease was categorized as: "localized" (31.3%), "regional" (38.9%), or "distant" (10.5%). We found significant associations between overall survival and sex, age, tumor location, facility type, hospital volume, reason for diagnosis, extent of disease, and surgical treatment. CONCLUSIONS: This is the first study to outline the epidemiology, clinical features, treatment, prognosis, and significant factors affecting prognosis of soft-tissue sarcoma in Japan using the National Cancer Registry. Documenting our data regarding elderly patients' outcomes is essential so other countries showing similar population-aging trends can learn from our experiences. LEVEL OF EVIDENCE: Prognostic studies, Level III.
    Nov. 2024, Japanese journal of clinical oncology, 54(11) (11), 1150 - 1157, English, International magazine
    Scientific journal

  • Continuous local antibiotic perfusion (CLAP) for fracture-related infection after reconstruction of primary alveolar soft part sarcoma in the right thigh: A case report
    Toshiyuki Takemori, Takuya Fujimoto, Ikuo Fujita, Toshiko Sakuma, Shunsuke Yahiro, Shoya Okuma, Daiya Kitazawa, Hirotsugu Muratsu, Akihiro Maruo
    Lead, Sep. 2024, JOS Case Reports, 3(3) (3), 163 - 167, English
    [Refereed]

  • Toshiyuki Takemori, Hitomi Hara, Teruya Kawamoto, Naomasa Fukase, Ryoko Sawada, Shuichi Fujiwara, Ikuo Fujita, Takuya Fujimoto, Masayuki Morishita, Shunsuke Yahiro, Tomohiro Miyamoto, Masanori Saito, Jun Sugaya, Katsuhiro Hayashi, Hiroyuki Kawashima, Tomoaki Torigoe, Tomoki Nakamura, Hiroya Kondo, Toru Wakamatsu, Munenori Watanuki, Munehisa Kito, Satoshi Tsukushi, Akihito Nagano, Hidetatsu Outani, Shunichi Toki, Shunji Nishimura, Hiroshi Kobayashi, Itsuo Watanabe, Yusuke Demizu, Ryohei Sasaki, Takumi Fukumoto, Tomoyuki Matsumoto, Ryosuke Kuorda, Toshihiro Akisue
    BACKGROUND: Few studies have compared the clinical outcomes of patients with pelvic bone sarcomas treated surgically and those treated with particle beam therapy. This is a multicenter retrospective cohort study which compared the clinical outcomes of patients with pelvic bone sarcoma who underwent surgical treatment and particle beam therapy in Japan. METHODS: A total of 116 patients with pelvic bone sarcoma treated at 19 specialized sarcoma centers in Japan were included in this study. Fifty-seven patients underwent surgery (surgery group), and 59 patients underwent particle beam therapy (particle beam group; carbon-ion radiotherapy: 55 patients, proton: four patients). RESULTS: The median age at primary tumor diagnosis was 52 years in the surgery group and 66 years in the particle beam group (P < 0.001), and the median tumor size was 9 cm in the surgery group and 8 cm in the particle beam group (P = 0.091). Overall survival (OS), local control (LC), and metastasis-free survival (MFS) rates were evaluated using the Kaplan-Meier method and compared among 116 patients with bone sarcoma (surgery group, 57 patients; particle beam group, 59 patients). After propensity score matching, the 3-year OS, LC, and MFS rates were 82.9% (95% confidence interval [CI], 60.5-93.2%), 66.0% (95% CI, 43.3-81.3%), and 78.4% (95% CI, 55.5-90.5%), respectively, in the surgery group and 64.9% (95% CI, 41.7-80.8%), 86.4% (95% CI, 63.3-95.4%), and 62.6% (95% CI, 38.5-79.4%), respectively, in the particle beam group. In chordoma patients, only surgery was significantly correlated with worse LC in the univariate analysis. CONCLUSIONS: The groups had no significant differences in the OS, LC, and MFS rates. Among the patients with chordomas, the 3-year LC rate in the particle beam group was significantly higher than in the surgery group.
    Lead, Jul. 2024, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, English, Domestic magazine
    Scientific journal

  • Shunsuke Yahiro, Teruya Kawamoto, Shuichi Fujiwara, Hitomi Hara, Naomasa Fukase, Ryoko Sawada, Toshiyuki Takemori, Tomohiro Miyamoto, Yutaka Mifune, Kenichiro Kakutani, Yuichi Hoshino, Shinya Hayashi, Tomoyuki Matsumoto, Takehiko Matsushita, Michiyo Koyanagi-Aoi, Takashi Aoi, Ryosuke Kuroda, Toshihiro Akisue
    Ewing sarcoma (ES) is an aggressive primary malignant bone tumor that predominantly affects children and young adults. Multimodal treatment approaches have markedly improved the survival of patients with localized ES. However, local recurrence and distant metastasis following curative therapies remain a main concern for patients with ES. Recent studies have suggested that slow‑cycling cells (SCCs) are associated with tumor progression, local recurrence and distant metastasis in various types of cancers. According to the results of these studies, it was hypothesized that SCCs may play a critical role in tumor progression, chemoresistance and local/distal recurrence in patients with ES. The present study applied a label‑retaining system using carboxyfluorescein diacetate succinimidyl ester (CFSE) to identify and isolate SCCs in ES cell lines. In addition, the properties of SCCs, including sphere formation ability, cell cycle distribution and chemoresistance, in comparison with non‑SCCs were investigated. RNA sequencing also revealed several upregulated genes in SCCs as compared with non‑SCCs; the identified genes not only inhibited cell cycle progression, but also promoted the malignant properties of SCCs. On the whole, the present study successfully identified SCCs in ES cells through a label‑retaining system using CFSE. Moreover, to the best of our knowledge, the present study is the first to describe the characteristic properties of SCCs in ES. The findings of this study, if confirmed, may prove to be useful in elucidating the underlying molecular mechanisms and identifying effective therapeutic targets for ES.
    Nov. 2022, International journal of oncology, 61(5) (5), English, International magazine
    Scientific journal

  • Toshiyuki Takemori, Teruya Kawamoto, Hitomi Hara, Naomasa Fukase, Shuichi Fujiwara, Ikuo Fujita, Takuya Fujimoto, Masayuki Morishita, Kazumichi Kitayama, Shunsuke Yahiro, Tomohiro Miyamoto, Masanori Saito, Jun Sugaya, Katsuhiro Hayashi, Hiroyuki Kawashima, Tomoaki Torigoe, Tomoki Nakamura, Hiroya Kondo, Toru Wakamatsu, Munenori Watanuki, Munehisa Kito, Satoshi Tsukushi, Akihito Nagano, Hidetatsu Outani, Shunichi Toki, Shunji Nishimura, Hiroshi Kobayashi, Itsuo Watanabe, Yusuke Demizu, Ryohei Sasaki, Takumi Fukumoto, Takahiro Niikura, Ryosuke Kuroda, Toshihiro Akisue
    This study aimed to retrospectively analyze the clinical outcomes of patients with pelvic and retroperitoneal bone and soft tissue sarcoma (BSTS). Overall, 187 patients with BSTS in the pelvis and retroperitoneal region treated at 19 specialized sarcoma centers in Japan were included. The prognostic factors related to overall survival (OS), local control (LC), and progression-free survival (PFS) were evaluated. The 3-year OS and LC rates in the 187 patients were 71.7% and 79.1%, respectively. The 3-year PFS in 166 patients without any distant metastases at the time of primary tumor diagnosis was 48.6%. Osteosarcoma showed significantly worse OS and PFS than other sarcomas of the pelvis and retroperitoneum. In the univariate analyses, larger primary tumor size, soft tissue tumor, distant metastasis at the time of primary tumor diagnosis, P2 location, chemotherapy, and osteosarcoma were poor prognostic factors correlated with OS. Larger primary tumor size, higher age, soft tissue tumor, chemotherapy, and osteosarcoma were poor prognostic factors correlated with PFS in patients without any metastasis at the initial presentation. Larger primary tumor size was the only poor prognostic factor correlation with LC. This study has clarified the epidemiology and prognosis of patients with pelvic and retroperitoneal BSTS in Japan.
    Lead, Jun. 2022, Cancers, 14(12) (12), English, International magazine
    Scientific journal

  • Toshiyuki Takemori, Teruya Kawamoto, Hitomi Hara, Naomasa Fukase, Shuichi Fujiwara, Kazumichi Kitayama, Shunsuke Yahiro, Tomohiro Miyamoto, Yutaka Mifune, Yuichi Hoshino, Kenichiro Kakutani, Tomoyuki Matsumoto, Takehiko Matsushita, Takahiro Niikura, Ryosuke Kuroda, Toshihiro Akisue
    PURPOSE: Soft tissue sarcomas (STSs) constitute a group of rare, heterogeneous tumors representing approximately 1% of all cancers. Owing to the rarity and pathological diversity of the disease, unplanned excision (UE) has often been performed for STS, resulting in an unfavorable prognosis. This study aimed to clarify clinical outcomes and prognostic factors in STS patients who underwent UE. PATIENTS AND METHODS: In a retrospective review of the medical records of patients with STS who underwent surgery at our institution between 1999 and 2015, patients were enrolled to either a UE group or a planned excision (PE) group. An analysis was then conducted to identify factors associated with prognosis after UE. RESULTS: Of 134 patients undergoing surgery for STS, 110 were enrolled to the PE group and 24 to the UE group. The median size of the primary tumor was significantly smaller, and more lesions were located in the superficial layer in the UE group than in the PE group. In addition, plastic reconstruction after additional radical resection was required significantly more often in the UE group than in the PE group. No significant difference in overall survival, local recurrence-free survival, or disease-free survival (DFS) between the UE and PE groups was observed; however, metastasis-free survival was significantly better in the UE group. In the UE group, poorer DFS was associated with older age (≥61 years) and a larger primary tumor (≥2.9 cm). CONCLUSION: A prognosis similar to that in patients undergoing PE could be achieved by appropriate additional surgeries in patients initially undergoing UE. However, UE for STS should be avoided, especially in older patients and those with a larger primary tumor.
    Lead, 2022, Cancer management and research, 14, 1815 - 1824, English, International magazine
    Scientific journal

  • Kazumichi Kitayama, Teruya Kawamoto, Yohei Kawakami, Hitomi Hara, Toshiyuki Takemori, Shuichi Fujiwara, Shunsuke Yahiro, Tomohiro Miyamoto, Yutaka Mifune, Yuichi Hoshino, Kenichiro Kakutani, Tomoyuki Matsumoto, Takehiko Matsushita, Takahiro Niikura, Ryosuke Kuroda, Toshihiro Akisue
    Osteolytic bone metastasis leads to skeletal‑related events, resulting in a decline in the patient activities and survival; therefore, it is important to understand the mechanism underlying bone metastasis. Recent studies have suggested that microRNAs (miRNAs or miRs) are involved in osteoclast differentiation and/or osteolytic bone metastasis; however, the roles of miRNAs have not been elucidated. In the present study, the roles of miRNAs in bone destruction caused by breast cancer metastasis were investigated in vitro and in vivo. miR‑16, miR‑133a and miR‑223 were transfected into a human breast cancer cell line, MDA‑MB‑231. The expression of osteolytic factors in conditioned medium (miR‑CM) collected from the culture of transfected cells was assessed. To evaluate the effects of miRNAs on osteoclast differentiation and activities, tartrate‑resistant acid phosphatase (TRAP) staining and bone resorptive assays were performed in osteoclasts following miR‑CM treatment. To create in vivo bone metastasis models for histological and morphometric evaluation, miRNA‑transfected MDA‑MB‑231 cells were transplanted into the proximal tibia of nude mice. Expression of osteolytic factors, including receptor activator for nuclear factor‑κB ligand (RANKL), interleukin (IL)‑1β, IL‑6, parathyroid hormone‑related protein (PTHrP), and tumor necrosis factor (TNF), was increased in miR‑16‑CM, whereas it was decreased in both miR‑133a‑CM and miR‑223‑CM. TRAP staining and bone resorptive assays revealed that osteoclast function and activities were promoted by miR‑16‑CM treatment, whereas they were suppressed by miR‑133a‑CM and miR‑223‑CM. Consistent with in vitro findings, in vivo experiments revealed that the overexpression of miR‑16 increased osteoclast activities and bone destruction in MDA‑MB‑231 cells, whereas the opposite results were observed in both miR‑133a‑ and miR‑223‑transfected MDA‑MB‑231 cells. Our results indicated that miR‑16 promoted osteoclast activities and bone destruction caused by breast cancer metastasis in the bone microenvironment, whereas miR‑133a and miR‑223 suppressed them. These miRNAs could be potential biomarkers and therapeutic targets for breast cancer bone metastasis.
    Nov. 2021, International journal of oncology, 59(5) (5), English, International magazine
    Scientific journal

  • Hitomi Hara, Yoshitada Sakai, Teruya Kawamoto, Naomasa Fukase, Yohei Kawakami, Toshiyuki Takemori, Shuichi Fujiwara, Kazumichi Kitayama, Shunsuke Yahiro, Tomohiro Miyamoto, Kenichiro Kakutani, Takahiro Niikura, Daisuke Miyawaki, Takuya Okada, Akihiro Sakashita, Yoshinori Imamura, Ryohei Sasaki, Yoshiyuki Kizawa, Hironobu Minami, Tomoyuki Matsumoto, Takehiko Matsushita, Ryosuke Kuroda, Toshihiro Akisue
    BACKGROUND: Skeletal related events due to metastatic bone tumors markedly affect the activities of daily living (ADL) and quality of life (QOL) in cancer patients. We focused on multidisciplinary therapy for metastatic bone tumors. This study aimed to evaluate the outcomes of surgical treatment for metastatic bone tumors in the extremities. METHODS: We retrospectively reviewed 114 patients who underwent surgical treatment for metastatic bone tumors of the extremities between 2008 and 2019 and 69 patients were reassessed for more than 6 months after surgery. The most common primary tumor was renal, followed by lung, thyroid, and breast cancers. We assessed 69 patients' performance status (PS), Barthel Index (BI) for ADL, EuroQol 5 Dimensions (EQ-5D) for QOL, and numerical rating scale (NRS) for pain and analyzed these postoperative values relative to preoperative values using Friedman's test. The postoperative overall survival and the prognostic factors were evaluated using the Kaplan-Meier method, the log-rank test and Cox proportional hazards analysis. RESULTS: The 1-year overall survival rate was 59%, and the median survival time after surgery was 20 months. Primary tumor, visceral metastasis, and surgical procedure were risk factors correlated with overall survival. PS, BI, EQ-5D, and NRS improved at 3 months after surgery and these improvements were maintained for 6 months after surgery regardless of the surgical procedure. CONCLUSIONS: The significant factors affecting survival after surgical treatment for bone metastases included the primary tumor, presence of visceral metastases, and internal fixation without tumor resection or curettage. Surgical treatment for metastatic bone tumors effectively reduced pain and improved PS, ADL, and QOL postoperatively after 3 months.
    Apr. 2021, Journal of bone oncology, 27, 100352 - 100352, English, International magazine
    Scientific journal

  • Toshiyuki Takemori, Teruya Kawamoto, Masayuki Morishita, Hitomi Hara, Naomasa Fukase, Yohei Kawakami, Shuichi Fujiwara, Kazumichi Kitayama, Shunsuke Yahiro, Tomohiro Miyamoto, Takuya Fujimoto, Ikuo Fujita, Yutaka Mifune, Yuichi Hoshino, Kenichiro Kakutani, Tomoyuki Matsumoto, Takehiko Matsushita, Takahiro Niikura, Ryosuke Kuroda, Toshihiro Akisue
    BACKGROUND/AIM: This study aimed to evaluate the association of clinical characteristics with treatment outcomes to ascertain the appropriate treatment options for soft tissue sarcomas (STS) patients with brain metastasis (BM). PATIENTS AND METHODS: Medical records of STS patients with BM who were treated in our institutions were retrospectively reviewed, and analyzed to identify the factors associated with post-BM survival. RESULTS: Among the 509 STS patients, BM occurred in five patients (0.98%). The median survival after BM was 1.5 months. Histological subtypes of the primary lesions in the five BM patients were: two synovial sarcomas, one myxoid liposarcoma, one alveolar soft part sarcoma, and one rhabdomyosarcoma. Among the five BM patients, the post-BM survival of two patients, who underwent surgery and postoperative radiotherapy, was longer than that of the other patients (p<0.01). CONCLUSION: Combined surgery and postoperative radiotherapy effectively managed symptoms and prolonged survival in STS patients with BM.
    Lead, Feb. 2021, Anticancer research, 41(2) (2), 1027 - 1034, English, International magazine
    Scientific journal

  • Kazuyoshi Mitani, Teruya Kawamoto, Hitomi Hara, Naomasa Fukase, Yohei Kawakami, Masayuki Morishita, Toshiyuki Takemori, Shuichi Fujiwara, Kazumichi Kitayama, Shunsuke Yahiro, Tomohiro Miyamoto, Masato Komatsu, Naoe Jimbo, Ryosuke Kuroda, Toshihiro Akisue
    Chondrolipoma is, based on the limited case reports available, an extremely rare histological variant of lipoma with the proliferation of mature adipocytes containing an area of true hyaline cartilage. Chondrolipoma is characterized by adult onset and is often identified in the breast, pharynx and tongue. The current study presents a case of chondrolipoma of the finger in an 11 year-old girl. Physical examination indicated a well-defined elastic soft mass, measuring 2.5x2 cm, on the dorsal aspect of the proximal phalanx of the left middle finger. Magnetic resonance imaging (MRI) revealed a well-circumscribed lesion with heterogeneous signal intensity. On T1- and T2-weighted images, the lesion indicated a predominantly marked hyperintense signal containing linear hypointense regions, and on fat-suppressed short-tau inversion recovery sequences, the lesion indicated a predominant hypointensity, with linear regions displaying hyperintensity. Marginal excision of the tumor was performed. Histologically, the major component of the tumor was mature adipose tissue containing a limited area of mature hyaline cartilage matrix, without lipoblasts or malignancy. The postoperative course of the patient was excellent, with no local recurrence three years after surgery. To the best of our knowledge, the current study outlines the first pediatric case of chondrolipoma arising in the finger.
    Jan. 2021, Molecular and clinical oncology, 14(1) (1), 2 - 2, English, International magazine
    Scientific journal

  • Shuichi Fujiwara, Teruya Kawamoto, Yohei Kawakami, Yasufumi Koterazawa, Hitomi Hara, Toshiyuki Takemori, Kazumichi Kitayama, Shunsuke Yahiro, Kenichiro Kakutani, Tomoyuki Matsumoto, Takehiko Matsushita, Takahiro Niikura, Michiyo Koyanagi-Aoi, Takashi Aoi, Ryosuke Kuroda, Toshihiro Akisue
    BACKGROUND: Cancer stem cells (CSCs) are considered to be responsible for tumor initiation, formation, and poor prognosis of cancer patients. However, the rarity of CSCs in clinical samples makes it difficult to elucidate characteristics of CSCs, especially in osteosarcoma (OS). The aim of this study is to verify whether it is possible to generate CSC-like cells by transducing defined factors into an OS cell line. METHODS: We retrovirally transduced the Octamer-binding transcription factor 3/4 (OCT3/4), Kruppel-like factor 4 (KLF4), and SRY-box transcription factor 2 (SOX2) genes into the MG-63 human OS cell line (MG-OKS). Parental and GFP-transduced MG-63 cells were used as negative control. We assessed the properties of the generated cells in vitro and in vivo. Multiple comparisons among groups were made using a one-way analysis of variance (ANOVA) followed by post hoc testing with Tukey's procedure. RESULTS: MG-OKS cells in vitro exhibited the significantly increased mRNA expression levels of CSC markers (CD24, CD26, and CD133), decreased cell growth, increased chemoresistance and cell migration, and enhanced sphere formation. Notably, MG-OKS cells cultured under osteogenic differentiation conditions showed strongly positive staining for both Alizarin Red S and alkaline phosphatase, indicating osteogenesis of the cells. Gene ontology analysis of microarray data revealed significant upregulation of epidermal-related genes. Tumors derived from MG-OKS cells in vivo were significantly larger than those from other cells in μCT analysis, and immunohistochemical staining showed that Ki-67, osteocalcin, and HIF-1α-positive cells were more frequently detected in the MG-OKS-derived tumors. CONCLUSIONS: In this study, we successfully generated OS CSC-like cells with significantly enhanced CSC properties following transduction of defined factors.
    Oct. 2020, Stem cell research & therapy, 11(1) (1), 429 - 429, English, International magazine
    Scientific journal

  • Teruya Kawamoto, Hitomi Hara, Masayuki Morishita, Naomasa Fukase, Yohei Kawakami, Toshiyuki Takemori, Shuichi Fujiwara, Kazumichi Kitayama, Shunsuke Yahiro, Tomohiro Miyamoto, Takuya Fujimoto, Ikuo Fujita, Kenichiro Kakutani, Tomoyuki Matsumoto, Takehiko Matsushita, Takahiro Niikura, Ryosuke Kuroda, Toshihiro Akisue
    Soft tissue sarcomas (STSs) are rare heterogeneous malignancies of mesenchymal origin. Pulmonary metastases develop in approximately 50% of the patients with high-grade STS, being the major cause of mortality in patients with metastatic STS. Pulmonary metastasectomy has been reported to contribute to long-term survival; however, an appropriate treatment has not been established. We aimed to identify factors associated with post-metastasis survival in STS patients with pulmonary metastasis and determine the appropriate treatment for each patient. We retrospectively reviewed the records of metastatic STS patients treated between 2000 and 2017 and analyzed the clinico-pathologic variables to identify factors associated with the survival. The median survival after pulmonary metastasis was 20.6 months, and the 1-, 3-, and 5-year survival rates were 68.6%, 36.0%, and 25.1%, respectively. The survival was significantly greater in patients who underwent pulmonary metastasectomy than in those without surgery (38.9 months vs. 10.5 months; p < 0.0001). Among those who did not undergo surgery, the survival was significantly greater in patients who received chemotherapy than in those without chemotherapy (19.1 months vs. 6.3 months, p = 0.037). Multivariate analysis identified pulmonary metastasectomy as the most important prognostic factor for post-metastasis survival (Hazard ratio 5.623; 95% Confidence Interval 2.733-11.572; p < 0.0001). In conclusion, pulmonary metastasectomy was the most important prognostic factor for post-metastasis survival in patients with metastatic STS. In addition, chemotherapy could prolong survival in patients who were not eligible for pulmonary resection. Although we should carefully weigh the risks and benefits, appropriate treatment for pulmonary metastases could contribute to long-time survival.
    Aug. 2020, Clinical & experimental metastasis, 37(4) (4), 509 - 517, English, International magazine
    Scientific journal

  • Yoshiki Takeoka, Takashi Yurube, Koichi Morimoto, Saori Kunii, Yutaro Kanda, Ryu Tsujimoto, Yohei Kawakami, Naomasa Fukase, Toshiyuki Takemori, Kaoru Omae, Yuji Kakiuchi, Shingo Miyazaki, Kenichiro Kakutani, Toru Takada, Kotaro Nishida, Masanori Fukushima, Ryosuke Kuroda
    Back pain is a global health problem with a high morbidity and socioeconomic burden. Intervertebral disc herniation and degeneration are its primary cause, further associated with neurological radiculopathy, myelopathy, and paralysis. The current surgical treatment is principally discectomy, resulting in the loss of spinal movement and shock absorption. Therefore, the development of disc regenerative therapies is essential. Here we show reduced disc damage by a new collagen type I-based scaffold through actinidain hydrolysis-Low Adhesive Scaffold Collagen (LASCol)-with a high 3D spheroid-forming capability, water-solubility, and biodegradability and low antigenicity. In human disc nucleus pulposus and annulus fibrosus cells surgically obtained, time-dependent spheroid formation with increased expression of phenotypic markers and matrix components was observed on LASCol but not atelocollagen (AC). In a rat tail nucleotomy model, LASCol-injected and AC-injected discs presented relatively similar radiographic and MRI damage control; however, LASCol, distinct from AC, decelerated histological disc disruption, showing collagen type I-comprising LASCol degradation, aggrecan-positive and collagen type II-positive endogenous cell migration, and M1-polarized and also M2-polarized macrophage infiltration. Reduced nucleotomy-induced disc disruption through spontaneous spheroid formation by LASCol warrants further investigations of whether it may be an effective treatment without stem cells and/or growth factors for intervertebral disc disease.
    Mar. 2020, Biomaterials, 235, 119781 - 119781, English, International magazine
    Scientific journal

  • Hitomi Hara, Teruya Kawamoto, Naomasa Fukase, Yohei Kawakami, Toshiyuki Takemori, Shuichi Fujiwara, Kazumichi Kitayama, Kotaro Nishida, Ryosuke Kuroda, Toshihiro Akisue
    BACKGROUND: The prognosis of patients with metastatic or advanced sarcomas is poor and there are few options for treatment. Several studies have shown that gemcitabine and docetaxel (GD) combination chemotherapy has antitumor activity against various subtypes of sarcoma. Recently, some studies have shown a favourable outcome for GD combination chemotherapy for relapsed high-grade osteosarcoma and spindle cell sarcoma of bone. If the effectiveness of GD is proven, this will result in new treatment options for advanced bone and soft tissue sarcomas (STS). The aim of this prospective Phase 2 study is to evaluate the efficacy and toxicity of the GD combination in patients with advanced bone sarcomas and STS. METHODS: This is a Phase 2, single-arm, open-label study to investigate the efficacy and safety of combination chemotherapy with GD for advanced bone sarcomas and STS and will enrol 20 patients. The patients will receive gemcitabine 900 mg/m2 on Days 1 and 8, and docetaxel 70 mg/m2 on Day 8 in 3-week cycles until disease progression or other evidence of treatment failure. The primary aim of this study is to analyse GD's effect on progression-free survival (PFS). The secondary objectives are to analyse treatment efficacy and safety in terms of response rate, tumour control rate, overall survival, and adverse event rate. The length of follow-up will be 5 years. DISCUSSION: This study will evaluate the efficacy and safety of combination therapy with gemcitabine and docetaxel for bone sarcomas and STS. If this combination proves to be acceptable, it could be used for as second, third, or later line therapy for patients with sarcomas (especially bone sarcomas). In the future, the role of various treatments, including GD therapy, will be clarified for specific subtypes of sarcoma. TRIAL REGISTRATION: This study was registered as UMIN000031004 (University Hospital Medical Information Network-Clinical Trial Registry: UMIN-CTR) on 1 March 1 2018 and with the Japan Registry of Clinical Trials (jRCT) as jRCTs051180042 on 30 January 2019. The posted information will be updated as needed to reflect protocol amendments and study progress.
    Jul. 2019, BMC cancer, 19(1) (1), 725 - 725, English, International magazine
    Scientific journal

  • Hitomi Hara, Teruya Kawamoto, Naomasa Fukase, Etsuko Katayama, Toshiyuki Takemori, Shuichi Fujiwara, Yoshitada Sakai, Kotaro Nishida, Ryosuke Kuroda, Toshihiro Akisue
    An infant boy underwent hip disarticulation for infantile fibrosarcoma immediately after birth. His rehabilitation began when he was 4 mos old and involved training with his left (residual) leg. He could stand with support at 12 mos. His initial prosthesis fitting was performed at the age of 13 mos. He could stand and walk with support at 15 mos of age and could walk with no additional support and go up and down stairs at 2 yrs. A single-axis prosthetic knee joint was introduced at the age of 2 yrs 3 mos. His first gait using a hip prosthesis was successful, and his prosthesis was replaced at appropriate intervals with no major problems. The authors believe that the key to achieving a successful prosthetic gait in children is good communication among the medical team, which should comprise an orthopedic doctor, rehabilitation doctor, nurse, physical therapist, prosthetist/orthotist, and the patient's parents.
    Oct. 2018, American journal of physical medicine & rehabilitation, 97(10) (10), e90-e92, English, International magazine
    Scientific journal

  • Toshiyuki Takemori, Teruya Kawamoto, Takeshi Ueha, Mitsunori Toda, Masayuki Morishita, Etsuko Kamata, Naomasa Fukase, Hitomi Hara, Shuichi Fujiwara, Takahiro Niikura, Ryosuke Kuroda, Toshihiro Akisue
    Hypoxia plays a significant role in cancer progression, including metastatic bone tumors. We previously reported that transcutaneous carbon dioxide (CO2) application could decrease tumor progression through the improvement of intratumor hypoxia. Therefore, we hypothesized that decreased hypoxia using transcutaneous CO2 could suppress progressive bone destruction in cancer metastasis. In the present study, we examined the effects of transcutaneous CO2 application on metastatic bone destruction using an animal model. The human breast cancer cell line MDA-MB-231 was cultured in vitro under three different oxygen conditions, and the effect of altered oxygen conditions on the expression of osteoclast-differentiation and osteolytic factors was assessed. An in vivo bone metastatic model of human breast cancer was created by intramedullary implantation of MDA-MB-231 cells into the tibia of nude mice, and treatment with 100% CO2 or a control was performed twice weekly for two weeks. Bone volume of the treated tibia was evaluated by micro-computed tomography (µCT), and following treatment, histological evaluation was performed by hematoxylin and eosin staining and immunohistochemical staining for hypoxia-inducible factor (HIF)-1α, osteoclast-differentiation and osteolytic factors, and tartrate-resistant acid phosphatase (TRAP) staining for osteoclast activity. In vitro experiments revealed that the mRNA expression of RANKL, PTHrP and IL-8 was significantly increased under hypoxic conditions and was subsequently reduced by reoxygenation. In vivo results by µCT revealed that bone destruction was suppressed by transcutaneous CO2, and that the expression of osteoclast-differentiation and osteolytic factors, as well as HIF-1α, was decreased in CO2-treated tumor tissues. In addition, multinucleated TRAP-positive osteoclasts were significantly decreased in CO2-treated tumor tissues. Hypoxic conditions promoted bone destruction in breast cancer metastasis, and reversal of hypoxia by transcutaneous CO2 application significantly inhibited metastatic bone destruction along with decreased osteoclast activity. The findings in this study strongly indicated that transcutaneous CO2 application could be a novel therapeutic strategy for treating metastatic bone destruction.
    Lead, Oct. 2018, Oncology reports, 40(4) (4), 2079 - 2087, English, International magazine
    Scientific journal

  • Masayuki Morishita, Hitomi Hara, Etsuko Katayama, Teruya Kawamoto, Naomasa Fukase, Toshiyuki Takemori, Shuichi Fujiwara, Kotaro Nishida, Ryosuke Kuroda, Toshihiro Akisue
    BACKGROUND: Chronic expanding hematoma is a rare entity resulting from trauma or surgery. This condition usually occurs in soft tissue, such as the trunk or extremities, while chronic expanding hematoma arising from bone has not been reported previously. We describe an unusual case of a huge intraosseous chronic expanding hematoma arising from the ilium, which had grown over a 40-year period following hip surgeries. CASE PRESENTATION: A 57-year-old Japanese woman presented with a 1.5-year history of right hip pain. She had a history of bilateral developmental dysplasia of the hip and had undergone bilateral arthroplasties in childhood. A physical examination revealed a large, firm, immobile mass at her right ilium. Based on radiographic findings, a type of slow-growing bone tumor was suspected, and an incisional biopsy was performed. A histopathologic examination revealed large amounts of old clotted blood within the lesion, and the capsule of the lesion was composed of dense, fibrous, connective tissue. There was no evidence of neoplasia, and chronic expanding hematoma was suspected. The lesion was resistant to conservative treatment, and so we performed an internal hemipelvectomy (including the capsule of the mass) and a reconstruction by hip transposition 2.5 years after the incisional biopsy. There was no recurrence of chronic expanding hematoma at the most recent follow-up of 1 year and 8 months postoperatively. CONCLUSIONS: A chronic expanding hematoma is characterized by its persistence and increasing size more than 1 month after the trauma or surgical event suspected of causing hemorrhage. To the best of our knowledge, this is the first report of chronic expanding hematoma arising from bone. We performed internal hemipelvectomy and hip transposition, and there has so far been no recurrence. This disease may be considered a differential diagnosis for bone tumor when the patient has a history of surgery or trauma, regardless of how many years have passed since the index event.
    Sep. 2018, Journal of medical case reports, 12(1) (1), 265 - 265, English, International magazine
    Scientific journal

  • Synergistic Effects of a Smac Mimetic with Doxorubicin Against Human Osteosarcoma.
    Etsuko Kamata, Teruya Kawamoto, Takeshi Ueha, Hitomi Hara, Naomasa Fukase, Masaya Minoda, Masayuki Morishita, Toshiyuki Takemori, Shuichi Fujiwara, Kotaro Nishida, Ryosuke Kuroda, Masahiro Kurosaka, Toshihiro Akisue
    BACKGROUND/AIM: Second mitochondria-derived activator of caspase (Smac) is a proapoptogenic mitochondrial protein that antagonizes inhibitors of apoptosis proteins (IAPs), resulting in induction of apoptosis. In the present study we investigated the effects of a Smac mimetic in combination with doxorubicin against osteosarcoma. MATERIALS AND METHODS: In vitro effects of the combination of a Smac mimetic AT-406 and doxorubicin on cell proliferation and apoptosis in osteosarcoma cell lines were examined using cell proliferation assays, flow cytometry, and immunoblot analyses. For in vivo experiments, human osteosarcoma xenografts were treated with combination of the two substances, and tumor volume and apoptotic activity in treated tumors were assessed. RESULTS: In vitro studies revealed that combination of the two substances significantly inhibited osteosarcoma proliferation with decreased cIAP1 expression and induced apoptosis in osteosarcoma cells. Combination of the two substances significantly suppressed osteosarcoma growth in vivo. Moreover, decreased cIAP1 expression and increased apoptotic activity were observed in tumors treated by their combination of the substances. CONCLUSION: The Smac mimetic AT-406 showed an apoptotic effect and a synergistic antitumor effect with doxorubicin on osteosarcoma. The combination of AT-406 and doxorubicin may serve as a novel therapeutic strategy for osteosarcoma treatment.
    Nov. 2017, Anticancer research, 37(11) (11), 6097 - 6106, English, International magazine
    Scientific journal

  • Masayuki Morishita, Teruya Kawamoto, Hitomi Hara, Yasuo Onishi, Takeshi Ueha, Masaya Minoda, Etsuko Katayama, Toshiyuki Takemori, Naomasa Fukase, Masahiro Kurosaka, Ryosuke Kuroda, Toshihiro Akisue
    The AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) modulates cellular energy metabolism, and promotes mitochondrial proliferation and apoptosis. Previous studies have shown that AICAR has anticancer effects in various cancers, however the roles of AMPK and/or the effects of AICAR on osteosarcoma have not been reported. In the present study, we evaluated the effects of AICAR on tumor growth and mitochondrial apoptosis in human osteosarcoma both in vitro and in vivo. For in vitro experiments, two human osteosarcoma cell lines, MG63 and KHOS, were treated with AICAR, and the effects of AICAR on cell growth and mitochondrial apoptosis were assessed by WST assays, TUNEL staining, and immunoblot analyses. In vivo, human osteosarcoma-bearing mice were treated with AICAR, and the mitochondrial proliferation and apoptotic activity in treated tumors were assessed. In vitro experiments revealed that AICAR activated AMPK, inhibited cell growth, and induced mitochondrial apoptosis in both osteosarcoma cell lines. In vivo, AICAR significantly reduced osteosarcoma growth without apparent body weight loss and AICAR increased both mitochondrial proliferation and apoptotic activity in treated tumor tissues. AICAR showed anticancer effects in osteosarcoma cells through an AMPK-dependent peroxisome proliferator‑activated receptor-γ coactivator-1α (PGC-1α)/mitochondrial transcription factor A (TFAM)/mitochondrial pathway. The findings in this study strongly suggest that AICAR could be considered as a potent therapeutic agent for the treatment of human osteosarcoma.
    Jan. 2017, International journal of oncology, 50(1) (1), 23 - 30, English, International magazine
    Scientific journal

  • Toshiyuki Takemori, Osamu Nakamura, Yoshiki Yamagami, Hideki Nishimura, Teruya Kawamoto, Toshihiro Akisue, Tetsuji Yamamoto
    INTRODUCTION: Most community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections affect skin or soft tissues, while invasive and life-threatening illnesses including osteomyelitis are less common. CA-MRSA infections occur especially in the pediatric age group, while the occurrence of CA-MRSA osteomyelitis in adults is uncommonly reported. PRESENTATION OF CASES: A rare case of acute osteomyelitis of the femur caused by Panton-Valentine leukocidin (PVL)-positive CA-MRSA in a 37-year-old man in good health is presented. A pure bone biopsy revealed extensive inflammation, suggestive of acute osteomyelitis, with no evidence of neoplasm, and PVL-positive MRSA was isolated from the culture. Antibiotic treatment, with 6 weeks of intravenous vancomycin and 4 weeks of clindamycin, followed by 2 weeks of oral linezolid, was given, and 2 years after treatment completion, there has been no relapse of infection. CONCLUSION: This case strongly suggests that we need to be aware of CA-MRSA osteomyelitis, which requires a high level of suspicion, prompt diagnosis, and appropriate antibiotic treatment.
    Lead, 2017, International journal of surgery case reports, 33, 4 - 7, English, International magazine
    Scientific journal

  • Toshiyuki Takemori, Kenichiro Kakutani, Koichiro Maeno, Toshihiro Akisue, Masahiro Kurosaka, Kotaro Nishida
    INTRODUCTION: Symptomatic perineural cysts are rare. Resection and closure of such cysts sometimes results in postoperative neurological deficits and they can recur. We report two cases of symptomatic perineural cysts treated with subarachnoid shunts. MATERIALS AND METHODS: Case 1: A 62-year-old woman presented with bladder dysfunction. We identified a cyst communicating with the subarachnoid space adjacent to the S2 nerve root and implanted a subarachnoid shunt. Seven years after this surgery, her bladder dysfunction had not recurred. Case 2: A 35-year-old woman had low back pain, radiculopathy and bladder dysfunction. We identified a cyst adjacent to the S1 nerve root and implanted a subarachnoid shunt. Her low back pain and radiculopathy improved immediately and she experienced neither postoperative neurological deficits nor recurrence. CONCLUSION: Cyst-subarachnoid shunts are a useful treatment option for symptomatic perineural cysts.
    Lead, May 2014, European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 23 Suppl 2, 267 - 70, English, International magazine
    Scientific journal

■ MISC
  • 真の医師の働き方改革を目指して 東京と神戸の働き方改革の違いと工夫
    澤田 良子, 竹森 俊幸, 深瀬 直政, 原 仁美, 秋末 敏宏, 黒田 良祐
    (一社)中部日本整形外科災害外科学会, Apr. 2026, 中部日本整形外科災害外科学会雑誌, 69(春季学会) (春季学会), 69 - 69, Japanese

  • 原 仁美, 深瀬 直政, 澤田 良子, 竹森 俊幸, 中松 裕太, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Mar. 2026, 日本整形外科学会雑誌, 100(2) (2), S533 - S533, Japanese

  • 戸田 雄, 小倉 浩一, 森實 千種, 佐竹 智行, 岩田 慎太郎, 小林 英介, 竹森 俊幸, 村松 脩大, 近藤 宏也, 東 尚弘, 川井 章
    (公社)日本整形外科学会, Mar. 2026, 日本整形外科学会雑誌, 100(3) (3), S1090 - S1090, Japanese

  • 深瀬 直政, 原 仁美, 澤田 良子, 竹森 俊幸, 中松 裕太, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Mar. 2026, 日本整形外科学会雑誌, 100(3) (3), S1254 - S1254, Japanese

  • 右脛骨に生じた良性骨腫瘍に対する有限要素法(FEM)を用いた術後のリハビリテーション医療
    藤本 卓也, 八尋 俊輔, 竹森 俊幸, 原 仁美, 酒井 良忠
    (公社)日本リハビリテーション医学会, Oct. 2025, The Japanese Journal of Rehabilitation Medicine, 62(秋季特別号) (秋季特別号), 374 - 374, Japanese

  • 高原 大一郎, 小林 英介, 岩田 慎太郎, 小倉 浩一, 尾崎 修平, 近藤 宏也, 竹森 俊幸, 下村 征史, 神尾 聡, 川井 章
    (公社)日本整形外科学会, Jun. 2025, 日本整形外科学会雑誌, 99(6) (6), S1322 - S1322, Japanese

  • 岩田 慎太郎, 竹森 俊幸, 近藤 宏也, 下村 征史, 神尾 聡, 高原 大一郎, 小倉 浩一, 尾崎 修平, 小林 英介, 川井 章
    (公社)日本整形外科学会, Jun. 2025, 日本整形外科学会雑誌, 99(6) (6), S1341 - S1341, Japanese

  • 竹森 俊幸, 小林 英介, 近藤 宏也, 下村 征史, 神尾 聡, 高原 大一郎, 尾崎 修平, 小倉 浩一, 岩田 慎太郎, 川井 章
    (公社)日本整形外科学会, Jun. 2025, 日本整形外科学会雑誌, 99(6) (6), S1342 - S1342, Japanese

  • 神尾 聡, 小倉 浩一, 佐藤 健二, 藤原 智洋, 中山 ロバート, 小池 宏, 遠藤 誠, 伊村 慶紀, 津田 祐輔, 米本 司, 森井 健司, 高原 大一郎, 下村 征史, 竹森 俊幸, 近藤 宏也, 尾崎 修平, 岩田 慎太郎, 小林 英介, 川井 章
    (公社)日本整形外科学会, Jun. 2025, 日本整形外科学会雑誌, 99(6) (6), S1370 - S1370, Japanese

  • 近藤 宏也, 小倉 浩一, 森實 千種, 佐竹 智行, 岩田 慎太郎, 戸田 雄, 村松 脩大, 竹森 俊幸, 小林 英介, 東 尚弘, 川井 章
    (公社)日本整形外科学会, Jun. 2025, 日本整形外科学会雑誌, 99(6) (6), S1379 - S1379, Japanese

  • 下村 征史, 岩田 慎太郎, 小林 英介, 小倉 浩一, 尾崎 修平, 近藤 宏也, 竹森 俊幸, 神尾 聡, 高原 大一郎, 川井 章
    (公社)日本整形外科学会, Jun. 2025, 日本整形外科学会雑誌, 99(6) (6), S1394 - S1394, Japanese

  • 原 仁美, 深瀬 直政, 澤田 良子, 竹森 俊幸, 藤原 周一, 中松 裕太, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2025, 日本整形外科学会雑誌, 99(6) (6), S1409 - S1409, Japanese

  • 竹森 俊幸, 小林 英介, 小倉 浩一, 近藤 宏也, 下村 征史, 神尾 聡, 高原 大一郎, 尾崎 修平, 岩田 慎太郎, 川井 章, 伊藤 公輝
    (公社)日本整形外科学会, Jun. 2025, 日本整形外科学会雑誌, 99(6) (6), S1437 - S1437, Japanese

  • 原 仁美, 深瀬 直政, 澤田 良子, 竹森 俊幸, 藤原 周一, 中松 裕太, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2025, 日本整形外科学会雑誌, 99(6) (6), S1455 - S1455, Japanese

  • 神尾 聡, 末原 義之, 池上 政周, 木村 葉, 来田 里奈, 高原 大一郎, 下村 征史, 竹森 俊幸, 近藤 宏也, 尾崎 修平, 小倉 浩一, 岩田 慎太郎, 小林 英介, 吉田 朗彦, 川井 章, 高阪 真路
    (公社)日本整形外科学会, Jun. 2025, 日本整形外科学会雑誌, 99(6) (6), S1501 - S1501, Japanese

  • 福島 俊, 岩田 慎太郎, 小林 英介, 小倉 浩一, 尾崎 修平, 赤澤 聡, 有川 真生, 景山 大輔, 戸田 雄, 村松 脩大, 鮒田 貴也, 竹森 俊幸, 近藤 宏也, 山内 良太, 川井 章
    西日本整形・災害外科学会, Mar. 2025, 整形外科と災害外科, 74(1) (1), 136 - 140, Japanese

  • がん骨転移チーム医療を学ぶ～自施設にリソースがない時の対応策～ 四肢長管骨・骨盤の骨転移への実践的アプローチ
    原 仁美, 深瀬 直政, 澤田 良子, 竹森 俊幸, 中松 裕太, 秋末 敏宏, 黒田 良祐
    (NPO)日本緩和医療学会, 2025, Palliative Care Research, 20(Suppl._Kansai) (Suppl._Kansai), S701 - S701, Japanese

  • 当院における大腿骨遠位腫瘍用人工膝関節置換術後の長期成績
    下村征史, 小倉浩一, 小林英介, 岩田慎太郎, 尾崎修平, 近藤宏也, 竹森俊幸, 神尾聡, 川井章
    2025, 日本整形外科学会雑誌(CD-ROM), 99(2) (2)

  • C-CATデータに基づく骨・軟部腫瘍領域のDNA/RNAがん遺伝子パネル検査の現状
    神尾聡, 神尾聡, 池上政周, 末原義之, 末原義之, 竹森俊幸, 尾崎修平, 小倉浩一, 岩田慎太郎, 小林英介, 吉田朗彦, 川井章, 高阪真路
    2025, 日本整形外科学会雑誌(CD-ROM), 99(2) (2)

  • 悪性骨・軟部腫瘍切除後の大腿骨広範欠損に対する血管柄付き遊離腓骨移植の有用性
    竹森俊幸, 小林英介, 有川真生, 戸田雄, 丹澤義一, 近藤宏也, 尾崎修平, 小倉浩一, 岩田慎太郎, 赤澤聡, 川井章
    (公社)日本整形外科学会, 2025, 日本整形外科学会雑誌(CD-ROM), 99(3) (3), S681 - S681, Japanese

  • 全国がん登録を用いた本邦における血管肉腫の特徴
    竹森俊幸, 小倉浩一, 森實千種, 佐竹智行, 岩田慎太郎, 戸田雄, 村松脩大, 近藤宏也, 小林英介, 東尚弘, 川井章
    (公社)日本整形外科学会, 2025, 日本整形外科学会雑誌(CD-ROM), 99(3) (3), S704 - S704, Japanese

  • NF1症例に生じた神経線維腫と悪性末梢神経鞘腫瘍の空間的ゲノム解析
    神尾聡, 神尾聡, 末原義之, 末原義之, 池上政周, 竹森俊幸, 尾崎修平, 小倉浩一, 岩田慎太郎, 小林英介, 吉田朗彦, 川井章, 高阪真路
    (公社)日本整形外科学会, 2025, 日本整形外科学会雑誌(CD-ROM), 99(3) (3), S674 - S674, Japanese

  • 上肢骨転移に対する手術成績
    原仁美, 深瀬直政, 竹森俊幸, 藤原周一, 秋末敏宏, 秋末敏宏, 黒田良祐
    (一社)中部日本整形外科災害外科学会, 2025, 中部日本整形外科災害外科学会雑誌, 68(春季学会) (春季学会), 68 - 68, Japanese

  • 病理学的な分類が困難だった悪性骨腫瘍の検討
    竹森 俊幸, 福島 俊, 下村 征史, 近藤 宏也, 小林 英介
    (一社)中部日本整形外科災害外科学会, Oct. 2024, 中部日本整形外科災害外科学会雑誌, 68(秋季学会) (秋季学会), 263 - 263, Japanese

  • 各地域のサルコーマセンター・希少がんセンターの現状と展望-効果的・効率的なチームとは?- 国立がん研究センター中央病院における肉腫への集学的アプローチ
    川井 章, 岩田 慎太郎, 小林 英介, 小倉 浩一, 尾崎 修平, 近藤 宏也, 竹森 俊幸, 神尾 聡, 下村 征史, 小島 勇貴, 下井 辰徳, 前嶋 愛子, 荒川 歩, 小川 千登世, 加藤 陽子
    (一社)日本癌治療学会, Oct. 2024, 日本癌治療学会学術集会抄録集, 62回, OSY10 - 1, English

  • 福島 俊, 秋元 哲夫, 岩田 慎太郎, 小林 英介, 小倉 浩一, 尾崎 修平, 戸田 雄, 村松 脩大, 鮒田 貴也, 竹森 俊幸, 近藤 宏也, 川井 章
    西日本整形・災害外科学会, Sep. 2024, 整形外科と災害外科, 73(4) (4), 685 - 687, Japanese

  • 日本における軟骨肉腫の統計 全国がん登録を用いた解析(Statistics of chondrosarcoma in Japan: Report from the population-based cancer registry in Japan)
    近藤 宏也, 小倉 浩一, 森實 千種, 佐竹 智行, 岩田 慎太郎, 戸田 雄, 村松 脩大, 竹森 俊幸, 小林 英介, 東 尚弘, 川井 章, 森實 千種
    (一社)日本癌学会, Sep. 2024, 日本癌学会総会記事, 83回, P - 1372, English

  • 竹森 俊幸, 小林 英介, 伊藤 公輝, 福島 俊, 尾崎 修平, 小倉 浩一, 岩田 慎太郎, 川井 章
    (公社)日本整形外科学会, Jun. 2024, 日本整形外科学会雑誌, 98(6) (6), S1533 - S1533, Japanese

  • 八尋 俊輔, 藤田 郁夫, 佐久間 淑子, 伊藤 達也, 藤本 卓也, 竹森 俊幸, 森下 雅之, 石田 剛
    (公社)日本整形外科学会, Jun. 2024, 日本整形外科学会雑誌, 98(6) (6), S1542 - S1542, Japanese

  • 近藤 宏也, 小林 英介, 竹森 俊幸, 鮒田 貴也, 村松 脩大, 戸田 雄, 関田 哲也, 福島 俊, 尾崎 修平, 小倉 浩一, 岩田 慎太郎, 川井 章
    (公社)日本整形外科学会, Jun. 2024, 日本整形外科学会雑誌, 98(6) (6), S1621 - S1621, Japanese

  • 再建血管の血流が途絶したが末梢側の血流が維持された大腿部悪性軟部腫瘍血行再建術後の2症例
    福島 俊, 岩田 慎太郎, 小林 英介, 小倉 浩一, 尾崎 修平, 戸田 雄, 村松 脩大, 鮒田 貴也, 竹森 俊幸, 近藤 宏也, 山内 良太, 景山 大輔, 有川 真生, 赤澤 聡, 川井 章
    西日本整形・災害外科学会, May 2024, 整形外科と災害外科, 73(Suppl.1) (Suppl.1), 171 - 171, Japanese

  • 竹森 俊幸, 小林 英介, 岩田 慎太郎, 小倉 浩一, 尾崎 修平, 福島 俊, 川井 章
    (公社)日本整形外科学会, Mar. 2024, 日本整形外科学会雑誌, 98(2) (2), S101 - S101, Japanese

  • 近藤 宏也, 岩田 慎太郎, 竹森 俊幸, 鮒田 貴也, 村松 脩大, 戸田 雄, 関田 哲也, 福島 俊, 尾崎 修平, 小倉 浩一, 小林 英介
    (公社)日本整形外科学会, Mar. 2024, 日本整形外科学会雑誌, 98(2) (2), S278 - S278, Japanese

  • 骨内病変は骨線維性異形成様アダマンチノーマで骨外病変は古典的アダマンチノーマを呈した脛骨腫瘍の1例
    八尋俊輔, 藤田郁夫, 佐久間淑子, 伊藤達也, 藤本卓也, 竹森俊幸, 森下雅之, 石田剛
    2024, 日本整形外科学会雑誌(CD-ROM), 98(6) (6)

  • 骨肉腫術前化学療法非奏効群(standard responder)の予後層別化にPET-CTのSUVmax変化率が有用である
    竹森俊幸, 小林英介, 伊藤公輝, 福島俊, 尾崎修平, 小倉浩一, 岩田慎太郎, 川井章
    2024, 日本整形外科学会雑誌(CD-ROM), 98(6) (6)

  • 血漿D-dimer測定によるスクリーニングは骨・軟部腫瘍周術期における術前静脈血栓塞栓症評価として有用である.
    近藤宏也, 小林英介, 竹森俊幸, 鮒田貴也, 村松脩大, 戸田雄, 関田哲也, 福島俊, 尾崎修平, 小倉浩一, 岩田慎太郎, 川井章
    2024, 日本整形外科学会雑誌(CD-ROM), 98(6) (6)

  • 森下 雅之, 藤田 郁夫, 小林 大介, 竹森 俊幸, 藤本 卓也, 北村 仁美, 米田 梓, 河本 和泉, 衣笠 真紀, 坂田 亮介, 薩摩 眞一
    (公社)日本整形外科学会, Nov. 2023, 日本整形外科学会雑誌, 97(11) (11), 1086 - 1088, Japanese

  • 陽子線治療を行った前腕悪性軟部腫瘍の2症例
    福島 俊, 秋元 哲夫, 岩田 慎太郎, 小林 英介, 小倉 浩一, 尾崎 修平, 戸田 雄, 村松 脩大, 鮒田 貴也, 竹森 俊幸, 近藤 宏也, 川井 章
    西日本整形・災害外科学会, Oct. 2023, 整形外科と災害外科, 72(Suppl.2) (Suppl.2), 191 - 191, Japanese

  • 藤本 卓也, 安藤 徹, 須藤 保, 藤田 郁夫, 角田 雅也, 竹森 俊幸, 河本 旭哉, 秋末 敏宏, 黒田 良祐, 鈴木 実
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1429 - S1429, Japanese

  • 深瀬 直政, 藤原 周一, 竹森 俊幸, 出水 祐介, 沖本 智昭, 澤田 良子, 原 仁美, 河本 旭哉, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1439 - S1439, Japanese

  • 竹森 俊幸, 河本 旭哉, 藤田 郁夫, 藤本 卓也, 原 仁美, 深瀬 直政, 澤田 良子, 藤原 周一, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1440 - S1440, Japanese

  • 竹森 俊幸, 藤本 卓也, 藤田 郁夫, 山本 茜, 小西 赳広, 北澤 大也, 小原 彬寛, 今泉 泰彦, 村津 裕嗣, 圓尾 明弘
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1452 - S1452, Japanese

  • 藤田 郁夫, 藤本 卓也, 竹森 俊幸, 山本 茜
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1461 - S1461, Japanese

  • 山本 茜, 竹森 俊幸, 藤本 卓也, 藤田 郁夫
    (公社)日本整形外科学会, Jun. 2023, 日本整形外科学会雑誌, 97(6) (6), S1487 - S1487, Japanese

  • 大腿神経完全麻痺に対して腱移行術を行い歩行能力が改善した1例
    竹森 俊幸, 藤本 卓也, 森下 雅之
    (公社)日本リハビリテーション医学会, May 2023, The Japanese Journal of Rehabilitation Medicine, 60(特別号) (特別号), 1 - 4, Japanese

  • 竹森 俊幸, 河本 旭哉, 藤田 郁夫, 藤本 卓也, 原 仁美, 深瀬 直政, 澤田 良子, 藤原 周一, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Mar. 2023, 日本整形外科学会雑誌, 97(3) (3), S957 - S957, Japanese

  • 藤田 郁夫, 藤本 卓也, 竹森 俊幸, 戸田 誠也
    (公社)日本整形外科学会, Mar. 2023, 日本整形外科学会雑誌, 97(2) (2), S94 - S94, Japanese

  • 藤本 卓也, 鈴木 実, 神谷 伸彦, 渡部 直史, 藤田 郁夫, 後村 大祐, 竹森 俊幸, 河本 旭哉, 秋末 敏宏, 黒田 良祐, 廣瀬 隆則
    (公社)日本整形外科学会, Mar. 2023, 日本整形外科学会雑誌, 97(3) (3), S833 - S833, Japanese

  • 竹森 俊幸, 河本 旭哉, 藤田 郁夫, 藤本 卓也, 原 仁美, 深瀬 直政, 澤田 良子, 藤原 周一, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Mar. 2023, 日本整形外科学会雑誌, 97(3) (3), S957 - S957, Japanese

  • 森下 雅之, 藤田 郁夫, 小林 大介, 竹森 俊幸, 藤本 卓也, 北村 仁美, 米田 梓, 河本 和泉, 衣笠 真紀, 坂田 亮介, 薩摩 眞一
    (公社)日本整形外科学会, Oct. 2022, 日本整形外科学会雑誌, 96(10) (10), 812 - 812, Japanese

  • 臼蓋に発生した淡明細胞型軟骨肉腫の1例
    戸田 誠也, 藤田 郁夫, 藤本 卓也, 竹森 俊幸
    (一社)中部日本整形外科災害外科学会, Oct. 2022, 中部日本整形外科災害外科学会雑誌, 65(秋季学会) (秋季学会), 301 - 301, Japanese

  • 八尋 俊輔, 藤原 周一, 河本 旭哉, 原 仁美, 深瀬 直政, 竹森 俊幸, 北山 和道, 宮本 智弘, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Sep. 2022, 日本整形外科学会雑誌, 96(8) (8), S1761 - S1761, Japanese

  • 宮本 智弘, 河本 旭哉, 深瀬 直政, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Sep. 2022, 日本整形外科学会雑誌, 96(8) (8), S1761 - S1761, Japanese

  • 八尋 俊輔, 藤原 周一, 河本 旭哉, 原 仁美, 深瀬 直政, 竹森 俊幸, 北山 和道, 宮本 智弘, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Sep. 2022, 日本整形外科学会雑誌, 96(8) (8), S1761 - S1761, Japanese

  • 宮本 智弘, 河本 旭哉, 深瀬 直政, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Sep. 2022, 日本整形外科学会雑誌, 96(8) (8), S1761 - S1761, Japanese

  • 河本 旭哉, 森下 雅之, 原 仁美, 深瀬 直政, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 宮本 智弘, 藤田 郁夫, 藤本 卓也, 藤田 昌秀, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2022, 日本整形外科学会雑誌, 96(6) (6), S1346 - S1346, Japanese

  • 竹森 俊幸, 河本 旭哉, 原 仁美, 深瀬 直政, 藤原 周一, 齊藤 正徳, 岩田 慎太郎, 林 克洋, 川島 寛之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2022, 日本整形外科学会雑誌, 96(6) (6), S1348 - S1348, Japanese

  • 小西 赳広, 竹森 俊幸, 河本 旭哉, 原 仁美, 深瀬 直政, 藤原 周一, 北山 和道, 八尋 俊輔, 宮本 智弘, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2022, 日本整形外科学会雑誌, 96(6) (6), S1352 - S1352, Japanese

  • 藤原 周一, 藤田 昌秀, 河本 旭哉, 藤田 郁夫, 藤本 卓也, 原 仁美, 深瀬 直政, 森下 雅之, 竹森 俊幸, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2022, 日本整形外科学会雑誌, 96(6) (6), S1356 - S1356, Japanese

  • 藤田 郁夫, 藤原 周一, 藤本 卓也, 森下 雅之, 河本 旭哉, 原 仁美, 深瀬 直政, 竹森 俊幸, 北山 和道, 八尋 俊輔, 宮本 智弘, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2022, 日本整形外科学会雑誌, 96(6) (6), S1371 - S1371, Japanese

  • 八尋 俊輔, 河本 旭哉, 原 仁美, 深瀬 直政, 竹森 俊幸, 藤原 周一, 北山 和道, 宮本 智弘, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2022, 日本整形外科学会雑誌, 96(6) (6), S1428 - S1428, Japanese

  • 島 稔樹, 竹森 俊幸, 河本 旭哉, 原 仁美, 秋末 敏宏, 黒田 良祐
    症例は11歳女児で、学校体育中に右膝痛が出現し、受診時には右膝近位部内側に軽度腫脹と圧痛がみられ、血液検査では炎症反応の軽度上昇を呈した。単純X線像、CT像では右脛骨近位部内側に溶骨性病変が描出され、MRIでは同部位にT1強調像で等信号、STIR像で高信号の異常信号域を認めたため、骨腫瘍、炎症性疾患の疑いで切開生検術を行った。病理組織学的検査では多数の炎症性細胞を認めたが、組織培養検査は陰性であり、骨シンチグラフィーとPET-CT検査で右脛骨近位部や右坐骨に集積を認めたため、慢性再発性多発性骨髄炎(CRMO)と診断した。非ステロイド性抗炎症薬(NSAIDs)内服のみで経過を観察し、術後1年2ヵ月時に左手関節にCRMO再発を認めたものの、初発・再発時ともNSAIDsにて症状は改善した。
    (一社)中部日本整形外科災害外科学会, May 2022, 中部日本整形外科災害外科学会雑誌, 65(3) (3), 403 - 404, Japanese

  • 手足に生じた軟部肉腫の予後に関する検討
    小西 赳広, 竹森 俊幸, 河本 旭哉, 深瀬 直政, 秋末 敏宏, 黒田 良祐
    (一社)中部日本整形外科災害外科学会, Apr. 2022, 中部日本整形外科災害外科学会雑誌, 65(春季学会) (春季学会), 123 - 123, Japanese

  • 八尋 俊輔, 河本 旭哉, 原 仁美, 竹森 俊幸, 藤原 周一, 北山 和道, 宮本 智弘, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Mar. 2022, 日本整形外科学会雑誌, 96(2) (2), S113 - S113, Japanese

  • 八尋 俊輔, 河本 旭哉, 原 仁美, 竹森 俊幸, 藤原 周一, 北山 和道, 宮本 智弘, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Mar. 2022, 日本整形外科学会雑誌, 96(2) (2), S113 - S113, Japanese

  • 慢性再発性多発性骨髄炎の一例
    島 稔樹, 竹森 俊幸, 河本 旭哉, 原 仁美, 秋末 敏宏, 黒田 良祐
    (一社)中部日本整形外科災害外科学会, Sep. 2021, 中部日本整形外科災害外科学会雑誌, 64(秋季学会) (秋季学会), 235 - 235, Japanese

  • 八尋 俊輔, 河本 旭哉, 原 仁美, 竹森 俊幸, 藤原 周一, 北山 和道, 宮本 智弘, 青井 貴之, 青井 三千代, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Aug. 2021, 日本整形外科学会雑誌, 95(8) (8), S1551 - S1551, Japanese

  • 北山 和道, 河本 旭哉, 原 仁美, 川上 洋平, 竹森 俊幸, 藤原 周一, 八尋 俊輔, 宮本 智弘, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Aug. 2021, 日本整形外科学会雑誌, 95(8) (8), S1621 - S1621, Japanese

  • 藤田 郁夫, 竹森 俊幸, 出水 祐介, 今井 礼子, 藤本 卓也, Nor Shazrina, 森下 雅之, 瀧上 俊作, 河本 旭哉, 原 仁美, 藤原 周一, 北山 和道, 八尋 俊輔, 宮本 智弘, 秋末 敏宏, 黒田 良祐, 沖本 智昭
    (公社)日本整形外科学会, Jun. 2021, 日本整形外科学会雑誌, 95(6) (6), S1273 - S1273, Japanese

  • 原 仁美, 河本 旭哉, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 宮本 智弘, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2021, 日本整形外科学会雑誌, 95(6) (6), S1343 - S1343, Japanese

  • 竹森 俊幸, 河本 旭哉, 原 仁美, 藤原 周一, 北山 和道, 八尋 俊輔, 宮本 智弘, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2021, 日本整形外科学会雑誌, 95(6) (6), S1352 - S1352, Japanese

  • 河本 旭哉, 森下 雅之, 藤田 郁夫, 原 仁美, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 宮本 智弘, 藤本 卓也, 瀧上 俊作, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2021, 日本整形外科学会雑誌, 95(6) (6), S1396 - S1396, Japanese

  • 藤田 郁夫, 竹森 俊幸, 出水 祐介, 今井 礼子, 藤本 卓也, Nor Shazrina, 森下 雅之, 瀧上 俊作, 河本 旭哉, 原 仁美, 藤原 周一, 北山 和道, 八尋 俊輔, 宮本 智弘, 秋末 敏宏, 黒田 良祐, 沖本 智昭
    (公社)日本整形外科学会, Jun. 2021, 日本整形外科学会雑誌, 95(6) (6), S1273 - S1273, Japanese

  • 藤本 卓也, 鈴木 実, 倉都 滋之, 藤田 郁夫, 森下 雅之, 須藤 保, 佐久間 淑子, 安藤 徹, 瀧上 俊作, 河本 旭哉, 原 仁美, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 宮本 智弘, 市川 秀喜, 秋末 敏宏, 黒田 良祐, 廣瀬 隆則
    (公社)日本整形外科学会, Jun. 2021, 日本整形外科学会雑誌, 95(6) (6), S1295 - S1295, Japanese

  • 原 仁美, 河本 旭哉, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 宮本 智弘, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2021, 日本整形外科学会雑誌, 95(6) (6), S1343 - S1343, Japanese

  • 竹森 俊幸, 河本 旭哉, 原 仁美, 藤原 周一, 北山 和道, 八尋 俊輔, 宮本 智弘, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2021, 日本整形外科学会雑誌, 95(6) (6), S1352 - S1352, Japanese

  • 北山 和道, 河本 旭哉, 原 仁美, 深瀬 直政, 川上 洋平, 竹森 俊幸, 藤原 周一, 八尋 俊輔, 宮本 智弘, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2021, 日本整形外科学会雑誌, 95(6) (6), S1364 - S1364, Japanese

  • 河本 旭哉, 森下 雅之, 藤田 郁夫, 原 仁美, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 宮本 智弘, 藤本 卓也, 瀧上 俊作, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2021, 日本整形外科学会雑誌, 95(6) (6), S1396 - S1396, Japanese

  • 河本 旭哉, 原 仁美, 森下 雅之, 藤田 郁夫, 藤本 卓也, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 宮本 智弘, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Mar. 2021, 日本整形外科学会雑誌, 95(3) (3), S897 - S897, Japanese

  • 河本 旭哉, 原 仁美, 森下 雅之, 藤田 郁夫, 藤本 卓也, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 宮本 智弘, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Mar. 2021, 日本整形外科学会雑誌, 95(3) (3), S897 - S897, Japanese

  • 肩関節周囲に生じた巨大な結節性偽痛風の1例
    北野 貴大, 河本 旭哉, 竹森 俊幸, 原 仁美, 黒田 良祐, 秋末 敏宏
    (一社)中部日本整形外科災害外科学会, Mar. 2021, 中部日本整形外科災害外科学会雑誌, 64(春季学会) (春季学会), 190 - 190, Japanese

  • 葛原 慎, 原 仁美, 竹森 俊幸, 大江 啓介, 秋末 敏宏, 黒田 良祐
    症例1(73歳男性)。甲状腺濾胞癌による右寛骨臼転移性腫瘍に対し病巣掻爬+スクリュー内固定+骨セメント充填が行なわれた。その結果、術後2日目から歩行器歩行が可能となり、術後7ヵ月経過現在、右股関節痛なく独歩可能である。症例2(46歳女性)。乳癌による左寛骨臼・大腿骨転移性骨腫瘍に対し病巣掻爬+スクリュー内固定+骨セメント充填が行なわれ、あわせて左大腿骨骨幹部転移性骨腫瘍に対し髄内釘による内固定を同時に施行した。その結果、術後13日目より平行棒内歩行が可能となり、術後8ヵ月経過現在、疼痛なく杖歩行可能である。
    (一社)中部日本整形外科災害外科学会, Jan. 2021, 中部日本整形外科災害外科学会雑誌, 64(1) (1), 73 - 74, Japanese

  • 竹森 俊幸, 国分 毅
    当院で上腕骨近位端骨折に対しロッキングプレートによる骨接合術を行った10例(男性3例、女性7例、平均年齢71.0歳)の術後成績について検討した。対象を術後6ヵ月時に肩関節拘縮を認めた群(拘縮あり群)2例と拘縮なし群8例に分けて比較したところ、術後6ヵ月時の平均自動可動域、JOAスコアは拘縮なし群が拘縮あり群と比較して有意に高値を示したが、外転・外旋筋力は両群間で有意差がみられなかった。また、単純レントゲンによるNSA、HHHは術直後、術後6ヵ月時、矯正損失量のいずれも両群間で有意差を認めなかった。一方、AHIは術直後と変化量が拘縮なし群で有意に高値を示したが、術後6ヵ月時には有意差はなかった。
    (一社)中部日本整形外科災害外科学会, Nov. 2020, 中部日本整形外科災害外科学会雑誌, 63(6) (6), 897 - 898, Japanese

  • がんロコモとリハビリテーション医学・医療 がんロコモと骨転移
    原 仁美, 酒井 良忠, 角谷 賢一朗, 竹森 俊幸, 北山 和道, 八尋 俊輔, 秋末 敏宏, 黒田 良祐
    (公社)日本リハビリテーション医学会, Nov. 2020, The Japanese Journal of Rehabilitation Medicine, 57(秋季特別号) (秋季特別号), S195 - S195, Japanese

  • 寛骨臼の転移性骨腫瘍に対して骨セメント充填及びスクリューによる内固定を行った2例
    葛原 慎, 河本 旭哉, 竹森 俊幸, 大江 啓介, 秋末 敏宏, 黒田 良祐
    (一社)中部日本整形外科災害外科学会, Oct. 2020, 中部日本整形外科災害外科学会雑誌, 63(秋季学会) (秋季学会), 95 - 95, Japanese

  • 八尋 俊輔, 河本 旭哉, 川上 洋平, 原 仁美, 竹森 俊幸, 藤原 周一, 北山 和道, 宮本 智弘, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Sep. 2020, 日本整形外科学会雑誌, 94(8) (8), S1856 - S1856, Japanese

  • 北山 和道, 河本 旭哉, 原 仁美, 深瀬 直政, 川上 洋平, 竹森 俊幸, 藤原 周一, 八尋 俊輔, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Sep. 2020, 日本整形外科学会雑誌, 94(8) (8), S1861 - S1861, Japanese

  • 藤原 周一, 河本 旭哉, 川上 洋平, 原 仁美, 竹森 俊幸, 北山 和道, 八尋 俊輔, 宮本 智弘, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Sep. 2020, 日本整形外科学会雑誌, 94(8) (8), S1982 - S1982, Japanese

  • 骨転移疼痛に対する集学的治療 -この痛みをどう治療するか- 転移性骨腫瘍に対する外科的治療
    原 仁美, 角谷 賢一朗, 酒井 良忠, 河本 旭哉, 竹森 俊幸, 秋末 敏宏, 黒田 良祐
    (一社)日本インターベンショナルラジオロジー学会, Aug. 2020, 日本インターベンショナルラジオロジー学会雑誌, 35(Suppl.) (Suppl.), 130 - 130, Japanese

  • 骨転移疼痛に対する集学的治療 -この痛みをどう治療するか- 転移性骨腫瘍に対する外科的治療
    原 仁美, 角谷 賢一朗, 酒井 良忠, 河本 旭哉, 竹森 俊幸, 秋末 敏宏, 黒田 良祐
    (一社)日本インターベンショナルラジオロジー学会, Aug. 2020, 日本インターベンショナルラジオロジー学会雑誌, 35(Suppl.) (Suppl.), 130 - 130, Japanese

  • がんロコモ 緩和ケアとがんロコモ
    原 仁美, 酒井 良忠, 河本 旭哉, 竹森 俊幸, 秋末 敏宏, 黒田 良祐
    (NPO)日本緩和医療学会, Aug. 2020, Palliative Care Research, 15(Suppl.) (Suppl.), S71 - S71, Japanese

  • 河本 旭哉, 森下 雅之, 藤田 郁夫, 原 仁美, 川上 洋平, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 藤本 卓也, 中松 裕太, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1449 - S1449, Japanese

  • 藤原 周一, 河本 旭哉, 川上 洋平, 小寺澤 康文, 原 仁美, 竹森 俊幸, 北山 和道, 八尋 俊輔, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1525 - S1525, Japanese

  • 北山 和道, 河本 旭哉, 原 仁美, 深瀬 直政, 川上 洋平, 竹森 俊幸, 藤原 周一, 八尋 俊輔, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1546 - S1546, Japanese

  • 竹森 俊幸, 森下 雅之, 河本 旭哉, 藤田 郁夫, 原 仁美, 川上 洋平, 藤原 周一, 北山 和道, 八尋 俊輔, 藤本 卓也, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jul. 2020, 日本整形外科学会雑誌, 94(6) (6), S1548 - S1548, Japanese

  • 上腕骨近位端骨折術後リハビリテーション医療が術後筋力・可動域改善に与える影響
    竹森 俊幸, 国分 毅
    (公社)日本リハビリテーション医学会, Jul. 2020, The Japanese Journal of Rehabilitation Medicine, 57(特別号) (特別号), 3 - 3, Japanese

  • 大広範囲腱板断裂に対する大腿筋膜補強を併用した鏡視下腱板修復術
    国分 毅, 竹森 俊幸, 美舩 泰, 乾 淳幸, 黒田 良祐
    (一社)中部日本整形外科災害外科学会, Apr. 2020, 中部日本整形外科災害外科学会雑誌, 63(春季学会) (春季学会), 90 - 90, Japanese

  • 上腕骨近位端骨折に対してロッキングプレートを用いた術後成績の検討
    竹森 俊幸, 国分 毅, 黒田 司, 筒井 美緒, 柴原 克紀
    (一社)中部日本整形外科災害外科学会, Apr. 2020, 中部日本整形外科災害外科学会雑誌, 63(春季学会) (春季学会), 205 - 205, Japanese

  • 河本 旭哉, 森下 雅之, 原 仁美, 川上 洋平, 藤田 郁夫, 藤本 卓也, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Mar. 2020, 日本整形外科学会雑誌, 94(2) (2), S338 - S338, Japanese

  • リプログラミング因子を用いた人工骨肉腫幹細胞株の樹立とその特性の探索
    藤原 周一, 河本 旭哉, 川上 洋平, 原 仁美, 深瀬 直政, 竹森 俊幸, 北山 和道, 八尋 俊輔, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Sep. 2019, 日本整形外科学会雑誌, 93(8) (8), S1679 - S1679, Japanese

  • がん骨転移における骨破壊に寄与するmiRNAの同定
    北山 和道, 河本 旭哉, 原 仁美, 深瀬 直政, 川上 洋平, 竹森 俊幸, 藤原 周一, 八尋 俊輔, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Sep. 2019, 日本整形外科学会雑誌, 93(8) (8), S1957 - S1957, Japanese

  • 藤原 周一, 河本 旭哉, 川上 洋平, 原 仁美, 深瀬 直政, 竹森 俊幸, 北山 和道, 八尋 俊輔, 青井 貴之, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Sep. 2019, 日本整形外科学会雑誌, 93(8) (8), S1679 - S1679, Japanese

  • 北山 和道, 河本 旭哉, 原 仁美, 深瀬 直政, 川上 洋平, 竹森 俊幸, 藤原 周一, 八尋 俊輔, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Sep. 2019, 日本整形外科学会雑誌, 93(8) (8), S1957 - S1957, Japanese

  • リプログラミング因子を用いた人工骨肉腫幹細胞株の樹立
    藤原 周一, 河本 旭哉, 川上 洋平, 小寺澤 康文, 原 仁美, 深瀬 直政, 竹森 俊幸, 北山 和道, 秋末 敏宏, 青井 貴之, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1416 - S1416, Japanese

  • 右足部軟部腫瘍の1例
    藤本 卓也, 藤田 郁夫, 佐久間 淑子, 森下 雅之, 須藤 保, 重本 理花, 河本 旭哉, 原 仁美, 深瀬 直政, 川上 洋平, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 廣瀬 隆則, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1350 - S1350, Japanese

  • Wait & see policyで初回治療を行った腹腔外デスモイド型線維腫症の検討
    藤田 郁夫, 河本 旭哉, 藤本 卓也, 森下 雅之, 重本 理花, 秋末 敏宏, 原 仁美, 深瀬 直政, 川上 洋平, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1373 - S1373, Japanese

  • 明細胞肉腫に対するLAT1阻害剤の抗腫瘍効果の検討
    森下 雅之, 藤本 卓也, 河本 旭哉, 秋末 敏宏, 藤田 郁夫, 竹森 俊幸, 藤原 周一, 北山 和道, 川上 洋平, 深瀬 直政, 原 仁美, 重本 理花, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1422 - S1422, Japanese

  • 粘液型脂肪肉腫の治療成績
    河本 旭哉, 森下 雅之, 藤田 郁夫, 原 仁美, 深瀬 直政, 川上 洋平, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 藤本 卓也, 重本 理花, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1497 - S1497, Japanese

  • 骨・軟部肉腫における脳転移症例の検討
    竹森 俊幸, 森下 雅之, 河本 旭哉, 藤田 郁夫, 原 仁美, 深瀬 直政, 川上 洋平, 藤原 周一, 北山 和道, 藤本 卓也, 重本 理花, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1516 - S1516, Japanese

  • 藤本 卓也, 藤田 郁夫, 佐久間 淑子, 森下 雅之, 須藤 保, 重本 理花, 河本 旭哉, 原 仁美, 深瀬 直政, 川上 洋平, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 廣瀬 隆則, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1350 - S1350, Japanese

  • 藤田 郁夫, 河本 旭哉, 藤本 卓也, 森下 雅之, 重本 理花, 秋末 敏宏, 原 仁美, 深瀬 直政, 川上 洋平, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1373 - S1373, Japanese

  • 藤原 周一, 河本 旭哉, 川上 洋平, 小寺澤 康文, 原 仁美, 深瀬 直政, 竹森 俊幸, 北山 和道, 秋末 敏宏, 青井 貴之, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1416 - S1416, Japanese

  • 森下 雅之, 藤本 卓也, 河本 旭哉, 秋末 敏宏, 藤田 郁夫, 竹森 俊幸, 藤原 周一, 北山 和道, 川上 洋平, 深瀬 直政, 原 仁美, 重本 理花, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1422 - S1422, Japanese

  • 河本 旭哉, 森下 雅之, 藤田 郁夫, 原 仁美, 深瀬 直政, 川上 洋平, 竹森 俊幸, 藤原 周一, 北山 和道, 八尋 俊輔, 藤本 卓也, 重本 理花, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1497 - S1497, Japanese

  • 竹森 俊幸, 森下 雅之, 河本 旭哉, 藤田 郁夫, 原 仁美, 深瀬 直政, 川上 洋平, 藤原 周一, 北山 和道, 藤本 卓也, 重本 理花, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2019, 日本整形外科学会雑誌, 93(6) (6), S1516 - S1516, Japanese

  • 四肢転移性骨腫瘍に対する外科的治療成績について
    原 仁美, 河本 旭哉, 深瀬 直政, 川上 洋平, 竹森 俊幸, 北山 和道, 酒井 良忠, 秋末 敏宏, 黒田 良祐
    (公社)日本リハビリテーション医学会, May 2019, The Japanese Journal of Rehabilitation Medicine, 56(特別号) (特別号), 1 - 9, English

  • 四肢転移性骨腫瘍に対する外科的治療成績について
    原 仁美, 河本 旭哉, 深瀬 直政, 川上 洋平, 竹森 俊幸, 北山 和道, 酒井 良忠, 秋末 敏宏, 黒田 良祐
    (公社)日本リハビリテーション医学会, May 2019, The Japanese Journal of Rehabilitation Medicine, 56(特別号) (特別号), 1 - 5, English

  • 原 仁美, 秋末 敏宏, 河本 旭哉, 深瀬 直政, 川上 洋平, 竹森 俊幸, 藤原 周一, 北山 和道, 黒田 良祐
    (公社)日本整形外科学会, Mar. 2019, 日本整形外科学会雑誌, 93(3) (3), S806 - S806, Japanese

  • 炭酸ガス経皮吸収による低酸素環境の改善が乳がん骨転移モデルの骨破壊を抑制する
    竹森 俊幸, 河本 旭哉, 戸田 光紀, 深瀬 直政, 原 仁美, 黒田 良祐, 秋末 敏宏
    (公社)日本リハビリテーション医学会, Oct. 2018, The Japanese Journal of Rehabilitation Medicine, 55(秋季特別号) (秋季特別号), S357 - S357, Japanese

  • 武岡 由樹, 由留部 崇, 森本 康一, 國井 沙織, 深瀬 直政, 竹森 俊幸, 垣内 裕司, 角谷 賢一朗, 高田 徹, 黒田 良祐, 西田 康太郎
    (公社)日本整形外科学会, Aug. 2018, 日本整形外科学会雑誌, 92(8) (8), S1733 - S1733, Japanese

  • 藤原 周一, 河本 旭哉, 青井 貴之, 小寺澤 康文, 原 仁美, 深瀬 直政, 蒲田 悦子, 竹森 俊幸, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Aug. 2018, 日本整形外科学会雑誌, 92(8) (8), S1812 - S1812, Japanese

  • 竹森 俊幸, 深瀬 直政, 森本 康一, 國井 沙織, 由留部 崇, 武岡 由樹, 河本 旭哉, 新倉 隆宏, 原 仁美, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Aug. 2018, 日本整形外科学会雑誌, 92(8) (8), S1999 - S1999, Japanese

  • 原 仁美, 河本 旭哉, 深瀬 直政, 川上 洋平, 竹森 俊幸, 藤原 周一, 北山 和道, 秋末 敏宏, 黒田 良祐
    (一社)日本骨折治療学会, Jul. 2018, 骨折, 40(Suppl.) (Suppl.), S40 - S40, Japanese

  • 原 仁美, 秋末 敏宏, 河本 旭哉, 深瀬 直政, 竹森 俊幸, 藤原 周一, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2018, 日本整形外科学会雑誌, 92(6) (6), S1412 - S1412, Japanese

  • 竹森 俊幸, 河本 旭哉, 上羽 岳志, 戸田 光紀, 蒲田 悦子, 藤原 周一, 深瀬 直政, 原 仁美, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2018, 日本整形外科学会雑誌, 92(6) (6), S1421 - S1421, Japanese

  • 河本 旭哉, 藤田 郁夫, 森下 雅之, 秋末 敏宏, 原 仁美, 深瀬 直政, 蒲田 悦子, 竹森 俊幸, 藤原 周一, 藤本 卓也, 北山 和道, 八尋 俊輔, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2018, 日本整形外科学会雑誌, 92(6) (6), S1478 - S1478, Japanese

  • 藤原 周一, 河本 旭哉, 原 仁美, 深瀬 直政, 蒲田 悦子, 竹森 俊幸, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2018, 日本整形外科学会雑誌, 92(6) (6), S1568 - S1568, Japanese

  • 新規低接着性コラーゲン(LASCol)はラット大腿骨骨欠損モデルにおいて骨癒合を促進する
    竹森 俊幸, 深瀬 直政, 森本 康一, 國井 沙織, 由留部 崇, 武岡 由樹, 原 仁美, 河本 旭哉, 黒田 良祐, 秋末 敏宏
    (公社)日本リハビリテーション医学会, May 2018, The Japanese Journal of Rehabilitation Medicine, 55(特別号) (特別号), 1 - 6, Japanese

  • 経皮炭酸ガス吸収による低酸素環境の改善は乳癌骨転移モデルの骨破壊を抑制できる
    竹森 俊幸, 河本 旭哉, 戸田 光紀, 深瀬 直政, 原 仁美, 黒田 良祐, 秋末 敏宏
    (公社)日本リハビリテーション医学会, May 2018, The Japanese Journal of Rehabilitation Medicine, 55(特別号) (特別号), 1 - 5, Japanese

  • 細胞低接着性コラーゲン(Low Adhesive Scaffold Collagen:LASCol)による脊椎椎間板再生
    武岡 由樹, 由留部 崇, 國井 沙織, 森本 康一, 竹森 俊幸, 深瀬 直政, 垣内 裕司, 角谷 賢一朗, 黒田 良祐
    (公社)日本リハビリテーション医学会, May 2018, The Japanese Journal of Rehabilitation Medicine, 55(特別号) (特別号), 1 - 2, Japanese

  • 河本 旭哉, 藤田 郁夫, 秋末 敏宏, 原 仁美, 深瀬 直政, 蒲田 悦子, 竹森 俊幸, 藤原 周一, 藤本 卓也, 森下 雅之, 黒田 良祐
    (公社)日本整形外科学会, Mar. 2018, 日本整形外科学会雑誌, 92(3) (3), S1248 - S1248, Japanese

  • 武岡 由樹, 由留部 崇, 國井 沙織, 森本 康一, 深瀬 直政, 竹森 俊幸, 垣内 裕司, 伊藤 雅明, 神田 裕太郎, 角谷 賢一朗, 高田 徹, 黒田 良祐, 西田 康太郎
    (一社)日本脊椎脊髄病学会, Mar. 2018, Journal of Spine Research, 9(3) (3), 233 - 233, Japanese

  • 竹森 俊幸, 河本 旭哉, 上羽 岳志, 戸田 光紀, 片山 悦子, 森下 雅之, 深瀬 直政, 原 仁美, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Aug. 2017, 日本整形外科学会雑誌, 91(8) (8), S1707 - S1707, Japanese

  • 原 仁美, 秋末 敏宏, 河本 旭哉, 深瀬 直政, 森下 雅之, 蒲田 悦子, 竹森 俊幸, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2017, 日本整形外科学会雑誌, 91(6) (6), S1323 - S1323, Japanese

  • 竹森 俊幸, 河本 旭哉, 上羽 岳志, 戸田 光紀, 片山 悦子, 森下 雅之, 深瀬 直政, 原 仁美, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Jun. 2017, 日本整形外科学会雑誌, 91(6) (6), S1324 - S1324, Japanese

  • 河本 旭哉, 藤田 郁夫, 秋末 敏宏, 原 仁美, 深瀬 直政, 森下 雅之, 蒲田 悦子, 竹森 俊幸, 藤本 卓也, 今堀 正也, 北山 和道, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2017, 日本整形外科学会雑誌, 91(6) (6), S1358 - S1358, Japanese

  • 深瀬 直政, 藤田 郁夫, 河本 旭哉, 藤本 卓也, 佐久間 淑子, 廣瀬 隆則, 神保 直江, 伊藤 智雄, 原 仁美, 森下 雅之, 蒲田 悦子, 竹森 俊幸, 秋末 敏宏, 黒田 良祐
    (公社)日本整形外科学会, Jun. 2017, 日本整形外科学会雑誌, 91(6) (6), S1394 - S1394, Japanese

  • 河本 旭哉, 原 仁美, 深瀬 直政, 森下 雅之, 片山 悦子, 竹森 俊幸, 田中 雄悟, 眞庭 謙昌, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Mar. 2017, 日本整形外科学会雑誌, 91(2) (2), S607 - S607, Japanese

  • 森下 雅之, 河本 旭哉, 蓑田 正也, 蒲田 悦子, 竹森 俊幸, 上羽 岳志, 深瀬 直政, 原 仁美, 黒田 良祐, 秋末 敏宏, 黒坂 昌弘
    (公社)日本整形外科学会, Aug. 2016, 日本整形外科学会雑誌, 90(8) (8), S1554 - S1554, Japanese

  • 蒲田 悦子, 河本 旭哉, 原 仁美, 深瀬 直政, 蓑田 正也, 森下 雅之, 竹森 俊幸, 上羽 岳志, 黒坂 昌弘, 黒田 良祐, 秋末 敏宏
    (公社)日本整形外科学会, Aug. 2016, 日本整形外科学会雑誌, 90(8) (8), S1556 - S1556, Japanese

  • 竹森 俊幸, 河本 旭哉, 上羽 岳志, 戸田 光紀, 蒲田 悦子, 森下 雅之, 蓑田 正也, 深瀬 直政, 原 仁美, 黒田 良祐, 秋末 敏宏, 黒坂 昌弘
    (公社)日本整形外科学会, Aug. 2016, 日本整形外科学会雑誌, 90(8) (8), S1558 - S1558, Japanese

  • 原 仁美, 秋末 敏宏, 河本 旭哉, 深瀬 直政, 蓑田 正也, 森下 雅之, 蒲田 悦子, 竹森 俊幸, 黒坂 昌弘
    (公社)日本整形外科学会, Jun. 2016, 日本整形外科学会雑誌, 90(6) (6), S1181 - S1181, Japanese

  • 蒲田 悦子, 河本 旭哉, 上羽 岳志, 原 仁美, 蓑田 正也, 森下 雅之, 竹森 俊幸, 黒田 良祐, 秋末 敏宏, 黒坂 昌弘
    (公社)日本整形外科学会, Jun. 2016, 日本整形外科学会雑誌, 90(6) (6), S1254 - S1254, Japanese

  • 竹森 俊幸, 河本 旭哉, 上羽 岳志, 戸田 光紀, 蒲田 悦子, 森下 雅之, 蓑田 正也, 深瀬 直政, 原 仁美, 黒田 良祐, 秋末 敏宏, 黒坂 昌弘
    (公社)日本整形外科学会, Jun. 2016, 日本整形外科学会雑誌, 90(6) (6), S1261 - S1261, Japanese

  • 壺坂 正徳, 鈴木 孝洋, 竹森 俊幸, 大島 隆司, 村津 裕嗣
    内反型膝OAに対してPS-TKAを施行した98例を対象に検討した。術中軟部組織バランスの評価方法は、OFR Tensorを用いてcomponent gapとvarus angleを計測し、得られた値からmedial compartment gap(MCG)とlateral compartment gap(LCG)を算出した。移動歩行能力の指標はTUGとし、術前と退院時の平均値を算出した。検討方法は、退院時のTUG改善秒数(術前TUG秒数-退院時TUG秒数)とMCG・LCGとの相関性について解析した。結果、MCGは有意な負の相関を示し、LCGは相関を示さなかった。
    (一社)日本関節鏡・膝・スポーツ整形外科学会, Apr. 2016, JOSKAS, 41(2) (2), 312 - 313, Japanese

  • 竹森 俊幸, 村津 裕嗣, 松本 知之, 鈴木 孝洋, 壺坂 正徳, 大島 隆司, 圓尾 明弘, 宮 秀俊, 黒田 良祐, 黒坂 昌弘
    TKAにおける軟部組織バランスの獲得にはModified gap法が有用と報告されているが、その手術手技は術者の経験を要し、完璧な靱帯バランス獲得を目指した過剰な内側解離は術後に膝内側不安定をきたす原因となる。そこで著者等は、TKA術後の膝内側安定性を重視し、Modified gap法に準じた新たな手技であるMedial gap technique(MGT)を考案し臨床応用してきた。また、著者等は以前、Measured resection法を用いたCR-TKA施行群とPS-TKA施行群の術中軟部組織バランスを群間比較し、CR-TKA群が有意に良好であったことを報告した。今回、MGTの有用性を検証するため、MGTを用いたCR-TKA施行群(70例)とPS-TKA施行群(70例)の術中軟部組織バランスを比較検討した。結果、有意な群間差は認めず、PS-TKAにおいてもCR-TKAと同等の術中軟部組織バランスを獲得できることが確認された。
    (一社)日本関節鏡・膝・スポーツ整形外科学会, Apr. 2016, JOSKAS, 41(2) (2), 324 - 325, Japanese

  • 鈴木 孝洋, 壺坂 正徳, 竹森 俊幸, 大島 隆司, 圓尾 明弘, 宮 秀俊, 村津 裕嗣
    当院で2008～2014年に膝関節のtransient bone marrow edema syndromeと診断された18例を対象とし、「性別」「年齢」「BMI」「職業」「発生部位」「X線所見」「MRI像」「荷重時痛の持続期間」「再発の有無」などについて検討した。性別は男性14例、女性4例、年齢は41～78歳(平均54.7歳)、BMIは20.5～30.5(平均25.0)であった。職業は、肉体労働に携わる重労働者はおらず、立ち仕事などの中労働者が5例(28%)、デスクワークや主婦などの軽労働者が11例(61%)、無職が2例(11%)であった。発生部位は、大腿骨内顆が9例(50%)、大腿骨外顆が8例(44%)、内外顆とも生じたものが1例(6%)であった。X線所見は、骨萎縮像を10例(56%)、関節症性変化を7例(39%)に認めた。MRIでのbone marrow edema(BME)像は、初診後平均4.5ヵ月で消失した。荷重時痛の持続期間は、初診後1～8ヵ月(平均3.9ヵ月)であった。BME消失後に下肢の他関節に再発したものが3例(17%)あり、再発部位は股関節や足関節、反対側の膝関節、同じ大腿骨の別の顆部などであった。
    (一社)日本関節鏡・膝・スポーツ整形外科学会, Apr. 2016, JOSKAS, 41(2) (2), 482 - 483, Japanese

  • 原 仁美, 秋末 敏宏, 酒井 良忠, 河本 旭哉, 深瀬 直政, 森下 雅之, 蒲田 悦子, 竹森 俊幸, 黒坂 昌弘
    (公社)日本整形外科学会, Mar. 2016, 日本整形外科学会雑誌, 90(3) (3), S859 - S859, Japanese

  • 竹森 俊幸, 村津 裕嗣, 松本 知之, 長井 寛斗, 鈴木 孝洋, 壺坂 正徳, 大島 隆司, 圓尾 明弘, 宮 秀俊, 黒田 良祐, 黒坂 昌弘
    PS型人工膝関節全置換術(TKA)における術後の膝安定性を評価するため、modified gap法に準じた新たな術式である、medial gap法(MGT)とmeasured resection法(MRT)について比較検討した。対象は内反型変形性膝関節症に対してMGTまたはMRTによる初回TKAを受けた60膝(MGT群30膝、MRT群30膝)で、術後1、6および12ヵ月の膝安定性を伸展位と屈曲位で比較した。伸展位の安定性はTelos SEを用いた10kg負荷の内外反ストレス撮影で、屈曲位のそれは1.5kg重錘負荷の上顆軸撮影で定量的に評価した。その結果、伸展位gap作成の骨切り量(大腿骨遠位と脛骨近位)は両群間で有意な差が見られなかったが、大腿骨後顆骨切り量はMGT群が有意に低かった。また、伸展位と屈曲位での内外の関節裂隙幅はいずれもMGT群が有意に低かった。これらの結果から、MGTはMRTに比べてPS-TKAの術後膝安定性が高いと思われた。
    (一社)日本人工関節学会, Dec. 2015, 日本人工関節学会誌, 45, 353 - 354, Japanese

  • 壺坂 正徳, 鈴木 孝洋, 竹森 俊幸, 大島 隆司, 圓尾 明弘, 宮 秀俊, 村津 裕嗣
    内反型変形性膝関節症に対して人工膝関節置換術を施行した69例(全例女性、平均74.6歳)を対象に、運動器不安定症(MADS)に対する早期治療効果を運動機能評価基準を用いて評価し、その回復に影響を及ぼす因子について検討した。MADS合併率の推移は、術前94%、術後2週93%、退院時90%であった。3m timed up and go test(TUG)は術後2週では有意に増悪したが、退院までの短期間に術前程度まで回復した。standing time(ST)は術後早期より改善を認め、術後2週から退院時にかけて有意に増加し、退院時には術前より有意な改善を認めた。TUGおよびSTに影響を及ぼした因子として、術後屈曲位内側関節裂隙開大距離が有意な相関を認めた。TKA術後の屈曲位内側安定性を獲得することが、術後の下肢機能の回復に重要であると考えられた。
    (一社)日本人工関節学会, Dec. 2015, 日本人工関節学会誌, 45, 905 - 906, Japanese

  • 竹森 俊幸, 圓尾 明弘, 鈴木 孝洋, 大島 隆司, 宮 秀俊, 村津 裕嗣
    鎖骨遠位端骨折に対し骨接合術を施行した67例を対象に、Scorpion plateを使用した18例とScorpion NEO plateを使用した4例の計22例(A群)と、Clavicle hook plateを使用した45例(B群)に分類した。単純X線で遠位主骨片の上下縁長を測定し、遠位骨片の大きさを比較した。また、術後合併症について検討を行った。その結果、全67例の遠位骨片上縁の平均値は15.9mm、下縁の平均値は22.9mmであった。各群での遠位骨片上縁はA群で17.6mm、B群で15.1mm、下縁はA群で23.9mm、B群で22.4mmであり、両群間に有意差を認めなかった。術後合併症は、B群で転倒による1例を含むhookの脱転を8例、hookの沈み込みを1例、遷延治癒を2例に認めたが、いずれの症例も抜釘時に骨癒合が得られていた為、再固定や固定材の追加は行わなかった。一方、A群で骨片の転位を1例に認め、hook plateへのconversionを行った。
    (一社)中部日本整形外科災害外科学会, Nov. 2015, 中部日本整形外科災害外科学会雑誌, 58(6) (6), 1141 - 1142, Japanese

  • 鈴木 孝洋, 圓尾 明弘, 竹森 俊幸, 大島 隆司, 宮 秀俊, 村津 裕嗣
    鎖骨遠位端骨折67例を対象に、受傷時の遠位骨片上縁と下縁の皮質骨の長さをX線で計測した。次に各種内固定材のテンプレートを用いてプレート遠位端からスクリューやフックまでの距離を測定した。それを基に遠位骨片をbicorticalに固定できると予想されるロッキングスクリューやフック数を計測した。その結果、遠位骨片長は上縁で平均15.9mm、下縁で22.9mmであった。遠位骨片に挿入可能なロッキングスクリューの平均本数は、ナカシマメディカル社NOW-J Plateが5.4本(径2.4mm)、Synthes社LCP Superior Clavicle Plateが3.5本(径2.7mm)、Stryker社VariAx Clavicle Superior Lateral Plateが3本(径2.7mm)、Acumed社Superior Distal Clavicle Plateが5.2本(径2.3mm)/2.3本(径3.5mm)であった。フックが遠位骨片の上面と下面にかかる症例は、アイメデック社のSCORPIONで44例(66%)、SCORPION NEOで64例(96%)であった。
    (一社)中部日本整形外科災害外科学会, Nov. 2015, 中部日本整形外科災害外科学会雑誌, 58(6) (6), 1161 - 1162, Japanese

  • 高島 良典, 圓尾 明弘, 竹森 俊幸, 大島 隆司, 宮 秀俊, 村津 裕嗣
    過去3年間に当科で骨軟部組織感染症に対し高濃度局所抗生剤投与を行った12例の治療成績について検討した。男性7例、女性5例で、平均年齢は53.8歳であった。全例、全身麻酔下に病巣掻爬術を行い、感染創部内に抗生剤注入用と排液用チューブを留置し、局所投与にはゲンタマイシン硫酸塩(GM)を用いた。その結果、局所投与期間は平均14.3日で、白血球数正常化までの期間は平均14.3日、CRP陰性化までの期間は平均20.1日であった。全例で炎症反応は陰性化し、経過観察中に再燃は認めなかった。GMによる副作用は認めず、最高血中濃度は3.5μg/mlの1例を除き、他はtraf域で安全域とされる2.0μg/ml以下で推移した。
    (一社)中部日本整形外科災害外科学会, May 2015, 中部日本整形外科災害外科学会雑誌, 58(3) (3), 523 - 524, Japanese

  • 壺坂 正徳, 高島 良典, 竹森 俊幸, 大島 隆司, 圓尾 明弘, 宮 秀俊, 村津 裕嗣
    (公社)日本整形外科学会, Mar. 2015, 日本整形外科学会雑誌, 89(3) (3), S776 - S776, Japanese

  • 竹森 俊幸, 村津 裕嗣, 松本 知之, 長井 寛斗, 高島 良典, 壺坂 正徳, 大島 隆司, 圓尾 明弘, 宮 秀俊, 黒田 良祐, 黒坂 昌弘
    (公社)日本整形外科学会, Mar. 2015, 日本整形外科学会雑誌, 89(3) (3), S903 - S903, Japanese

  • 竹森 俊幸, 真柴 賛, 森 正樹, 岩田 憲, 高田 成基, 山本 哲司
    68歳女。ハンセン病の後遺症があり、10年ほど前から左膝外反変形が出現し、最近進行して歩行困難となったため当科を紹介受診した。単純X線像でFTAが133°と高度外反変形を認め、また、高度の骨破壊による大腿骨・脛骨外側の骨欠損や巨大遊離体を認めた。神経学的検査では、下腿以下の知覚鈍麻、足関節以下の知覚脱失、足関節以下の完全運動麻痺、下肢振動覚の低下、下腿腱反射の消失を認め、左Charcot膝関節と診断した。TKAを施行し、術後合併症はなく、術後4週間で歩行器歩行が安定し転院となった。術後2年の現在、人工関節の部品は安定しており、FTAは174°とアライメントも良好で、歩行はT字杖とカート使用で外出可能となっている。
    (一社)日本人工関節学会, Dec. 2014, 日本人工関節学会誌, 44, 851 - 852, Japanese

  • 骨軟部感染症に対する高濃度局所抗生剤投与の経験
    高島 良典, 圓尾 明弘, 竹森 俊幸, 大島 隆司, 宮 秀俊, 村津 裕嗣
    (一社)中部日本整形外科災害外科学会, Sep. 2014, 中部日本整形外科災害外科学会雑誌, 57(秋季学会) (秋季学会), 233 - 233, Japanese

  • 交通外傷後の瘢痕より生じた多発性有棘細胞癌の1例
    横井 郁美, 森下 徹也, 森上 純子, 竹森 俊幸, 山上 佳樹, 斉藤 まり, 窪田 泰夫
    (一社)日本皮膚悪性腫瘍学会, Jul. 2014, 日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 30回, 148 - 148, Japanese

  • 竹森 俊幸, 中村 修, 加地 良雄, 山口 幸之助, 山本 哲司
    症例1は60歳男で、小指の伸展制限を主訴に受診した。手術はY-V形成とZ形成を用いた皮切をデザインした。術翌日から手指の可動域訓練を開始した。術後3週で上皮化は完成し、伸展制限は著明に改善し、完全屈伸展が可能となった。術後3ヵ月で再発は認めていない。症例2は79歳男で、小指の伸展障害を主訴に受診した。手術はY-V形成とZ形成を用いた皮切をデザインした。術後3週で上皮化は完成し、小指の完全屈伸展が可能となった。術後1年で再発は認めていない。
    (一社)中部日本整形外科災害外科学会, May 2014, 中部日本整形外科災害外科学会雑誌, 57(3) (3), 655 - 656, Japanese

  • Dupuytren拘縮に対する創部開放療法に人工真皮被覆を併用した2例
    竹森 俊幸, 中村 修, 加地 良雄, 山口 幸之助, 山本 哲司
    (一社)中部日本整形外科災害外科学会, Sep. 2013, 中部日本整形外科災害外科学会雑誌, 56(秋季学会) (秋季学会), 244 - 244, Japanese

  • 岸本 真一郎, 牧野 健, 竹森 俊幸, 濱本 秀樹
    12歳女。右肩関節痛、発熱を主訴とした。特に誘因なく主訴が出現し、前医受診時の単純X線像で明らかな異常は指摘されなかったが、6日後の紹介受診時には右肩関節周囲の腫脹とCRP上昇がみられ、単純X線像、MRIでは上腕骨頭の下方偏位、右肩関節の亜脱臼と肩関節内の著明な関節液貯留を認めた。化膿性肩関節炎を疑って関節穿刺を行い、培養検査でメチシリン感受性黄色ブドウ球菌を認めたため、全身麻酔下に関節切開排膿術、洗浄、デブリドマン、ドレナージと抗生物質の投与を行った。術後経過は良好で、術後3ヵ月現在、右肩関節の可動域制限はなく、亜脱臼位や感染の再燃は認めていない。本例ではMRIで骨髄内への炎症はみられず、血行性に関節内へ感染が進展したと考えられた。
    (株)南江堂, Sep. 2012, 整形外科, 63(10) (10), 1049 - 1051, Japanese

  • 竹森 俊幸, 角谷 賢一朗, 前野 耕一郎, 黒坂 昌弘, 西田 康太郎
    Perineural cyst(PC)のほとんどは無症候性であり、その場合には治療は不要であるが、症候性の場合には手術療法の適応となりうる。手術法としては、嚢腫切除術、交通孔閉鎖術、嚢腫縫縮・形成術、シャント術など様々な報告があるが、確立された方法は未だない。今回著者等は、会陰部痛や膀胱直腸障害などを呈した症候性PCの2例(62歳女、35歳女)に対して嚢腫-クモ膜下シャント術を行い、良好な結果が得られたので報告した。
    (一社)中部日本整形外科災害外科学会, Jul. 2012, 中部日本整形外科災害外科学会雑誌, 55(4) (4), 865 - 866, Japanese

  • 竹森 俊幸, 濱本 秀樹, 岸本 真一郎, 牧野 健
    症例は17歳男性で、空手の試合中に受傷し、右母指指節間(IP)関節の自動伸展制限が出現した。自動伸展は-45°、屈曲80°で、他動的には完全伸展可能であった。X線で明らかな骨折は認めず、MRIでは右母指IP関節レベルで右長母指伸筋(EPL)腱皮下断裂像が認められた。骨折を伴わない非開放性のmallet thumbと診断し、受傷5日目に手術を施行した。EPL腱は付着部より4mm近位で完全断裂しており、断端は4mm離開していた。IP関節伸展0°で1.2mm径のKirschner鋼線を用いて関節固定し、4-0ループ針2本でcore sutureを行い、5-0ナイロンで補助縫合を追加した。術後4週でKirschner鋼線の抜去を行い、アルフェンスシーネ固定を除去し自動運動を開始した。更に4週間は夜間のみコイルスプリントを装着した。術後6ヵ月で可動域は自動伸展-5°、屈曲75°となり、ピンチ力も健側比100%まで回復して動作時痛、圧痛もなく、スポーツ活動に復帰した。
    (一社)中部日本整形外科災害外科学会, Mar. 2012, 中部日本整形外科災害外科学会雑誌, 55(2) (2), 323 - 324, Japanese

■ Research Themes
  • Effects of an antioxidant flavonoid on muscle atrophy associated with cachexia in pediatric osteosarcoma
    深瀬 直政, 澤田 良子, 原 仁美, 藤原 周一, 秋末 敏宏
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2024 - 31 Mar. 2027
    本年度は研究計画に基づき、フィセチンの骨格筋におけるROS（活性酸素種）抑制効果の検証を中心に実験を進めている。まず、in vitro実験においては、C2C12筋芽細胞を用いてフィセチンの酸化ストレス軽減効果の検討を行っている。10μM、50μM、100μMの各濃度でフィセチン処理を行い、ROS assay kitを用いて細胞内ROS産生量の測定実験を実施中である。 また、筋萎縮関連因子であるAtrogin-1の発現についてもRT-PCRおよびウェスタンブロット法による評価を進めており、フィセチン処理がAtrogin-1の発現に与える影響を検証している。これらの実験を通じて、フィセチンがROS産生を抑制することで筋萎縮シグナル経路を抑制する可能性について明らかにしていく予定である。並行して、マウス骨肉腫細胞株LM8に対するフィセチンの効果についても検討を開始しており、がん細胞の増殖に対するフィセチンの影響を調査している。この実験により、フィセチンの抗腫瘍効果の可能性についても検証を進めている。in vivo実験に向けた準備として、C3Hマウスを用いた骨肉腫モデルの確立を進めており、フィセチン投与プロトコルの最適化を行っている。次年度に予定している本格的なin vivo実験に向けて、動物実験の体制整備を進めている段階である。 現在、これらの実験からデータを収集している段階であり、フィセチンが骨格筋における酸化ストレスを効果的に軽減し、筋萎縮を抑制する可能性について検証を続けている。また、抗腫瘍効果についても引き続き研究を進めている。今後は実験結果を詳細に分析し、次年度のin vivo実験へとつなげていく予定である。

  • サルコペニアの骨格筋に対する経皮的炭酸ガス投与法の効果について
    原 仁美, 竹森 俊幸, 河本 旭哉, 藤原 周一, 秋末 敏宏, 深瀬 直政, 澤田 良子
    日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 01 Apr. 2022 - 31 Mar. 2025
    サルコペニアの成因や病態については明らかにされていない部分も多く、基礎研究が進行中であるが、臨床的には診断ガイドラインも作成されており、予防や治療法の確立が望まる。現在のところ、有効な治療法としてエビデンスが示されているのは運動療法だけであり、薬物治療や栄養療法についてのエビデンスは不十分である。サルコペニアはロコモティブシンドローム、フレイルと並んで高齢者の運動機能、身体機能の低下として問題となるが、高齢者では、運動器の慢性変性疾患による疼痛やしびれなどの自覚症状を有することが多く、さらに基礎疾患による運動制限や認知機能や気力の低下もあるため、運動療法を習慣化させることが困難である。経皮的炭酸ガス療法は運動能力が低下した状態においても施術が可能で低侵襲な新規治療法として、我々は既に骨折や悪性軟部腫瘍に対する臨床研究を行っている。有酸素運動と同様の効果が得られる本治療法が、サルコペニアに対して有効であることが示されれば、臨床応用ができ、高齢社会において大きく貢献することが可能であると考える。 そのためにはまず、自然発症高血圧ラット（SHR）に高脂肪高炭水化物食を負荷したモデル（サルコペニアラット）を使用し、経皮的炭酸ガス療法を行う。経皮的炭酸ガス治療群とコントロール群で体組成の評価を行い、摘出した骨格筋組織で病理組織学的、分子生物学的に筋量や筋サテライト細胞数の評価、筋タンパクの合成と分解に関連する因子についての評価を行う予定である。

  • Dormant cellを用いたEwing肉腫新規治療の開発
    竹森 俊幸
    日本学術振興会, 科学研究費助成事業, 若手研究, 神戸大学, 01 Apr. 2022 - 31 Mar. 2025
    我々は、Tet on systemをEwing肉腫細胞株RD-ESに導入し、がんの再発・転移に関与していると考えれれているdormant cellを同定・分離し、その特徴を報告してきた。また、より効率的にdormant cellを得るために、Tet on systemと類似している、細胞内酵素と反応し蛍光を発するcarboxyfluorescein diacetate succinimidyl ester (CFSE)を用いた方法でのdormant cellの同定・分離実験も行った。細胞はCFSEと反応すると蛍光を発するようになる。その後、細胞分裂により娘細胞に蛍光が分散される。従って、分裂を繰り返す細胞は徐々に蛍光が減弱していき、dormant cellのように分裂しない細胞ほど強い蛍光を保持することになる。この現象を利用してCFSE反応後5日間培養した時点で蛍光が強い上位10%の細胞をdormant cellを含む細胞周期の非常に遅い細胞群slow-cycling cells(SCCs)と定義し、SCCsとそれ以外の集団であるNon-SCCsを比較することで、SCCsが過去の他がん種で報告されているdormant cellに類似する特徴を有することを証明した。

  • Basic research about fluid-fluid phase separation and membraneless organelles in sarcoma
    秋末 敏宏, 河本 旭哉, 竹森 俊幸, 原 仁美, 深瀬 直政, 藤原 周一
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Challenging Research (Exploratory), Kobe University, 09 Jul. 2021 - 31 Mar. 2025
    2023年度（令和５年度）においては、骨肉腫細胞株MG63、KHOS、LM8、SaOS2中のストレス顆粒関連タンパク質(TIA-1、TIAR、G3BP1、G3BP2、CAPRIN-1、USP10)の 発現の有無をウェスタンブロットで再評価した。その結果、これらの細胞株で普通の培養下でストレス顆粒タンパク質が発現していることを再度確認した。また、ストレス顆粒関連タンパク質について、in vitroで各細胞株において蛍光免疫染色を行い共焦点レーザー顕微鏡で発現と局在を調べる。更にin vitroで低酸素環境下（酸素１％および5％）と通常酸素状態（酸素20％）のストレス顆粒タンパク質の遺伝子・タンパク質レベルでの発現の確認を開始した。 これらの細胞株のうちMG63にレトロウイルスを用いてOCT3/4、KLF4,SOX2を導入し、人工骨肉腫幹細胞MG-OKSを作製した。MG-OKSの網羅的遺伝子解析でMG-63に比し有意な発現上昇を認めた遺伝子から、がん関連の報告があるSPRR1Aに着目し、in vitroにてMG-OKSにSPRR1A選択的siRNAを導入し(siMG-OKS)、SPRR1Aの発現をqRT-PCRで確認し、細胞形態を位相差顕微鏡で観察した。細胞増殖能をWST-8 assayでMG-OKSとsiMG-OKSで比較検討した。結果は、qRT-PCRにてsiMG-OKSでSPRR1Aの発現低下を確認した。siMG-OKSはMG-OKSと比較し細胞増殖能が有意に低下していた。

  • Development of new treatment strategies for osteosarcoma using induced osteosarcoma stem cells
    Kawamoto Teruya
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2021 - 31 Mar. 2024
    The purpose of this study was to explore the new therapeutic targets in osteosarcoma using MG-OKS, an engineered osteosarcoma stem cells, that we have successfully generated in a previous study. We focused on SPRR1A, which was significantly upregulated in the engineered osteosarcoma stem cells MG-OKS compared to the parental cell line MG-63. We investigated the roles of SPRR1A in osteosarcoma by inhibition of SPRR1A expression in MG-OKS using selective siRNA. In vitro, we found that alternation in cell morphology, and decreased cell proliferation and migration abilities in SPRR1A inhibited MG-OKS, and in vivo, a decrease in tumorigenicity and Ki-67 expression was observed. Comprehensive genetic analysis showed that the expression of genes related to cell adhesion and the cell cycle was altered. These results suggest that SPRR1A may be a new therapeutic target for osteosarcoma.

  • Identification of Dormant Cells in Ewing sarcoma
    Takemori Toshiyuki
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Research Activity Start-up, Kobe University, 11 Sep. 2020 - 31 Mar. 2022
    The mechanical of local recurrence and distant metastases of cancer remains unclear. Recently, dormant cell, which is a very small population, has been suggested to be involved in local recurrence and distant metastasis of cancer, but there are no reports of dormant cell in Ewing's sarcoma. We have demonstrated that cells identified and isolated from existing Ewing's sarcoma cell lines using the Tet on system have the characteristics of dormant cells with low proliferative capacity and resistance to anticancer drugs.

  • Antitumor effects of transcutaneous carbon dioxide therapy on stemness in bone and soft tissue sarcomas
    KAWAMOTO Teruya, FUKASE Naomasa, MINODA Masaya, MORISHITA Masayuki, HARADA Risa, TAKEMORI Toshiyuki, KAMATA Etsuko
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2014 - 31 Mar. 2017
    To establish a novel therapeutic strategy for bone and soft tissue sarcomas, we hypothesized that "Pluripotency" and "Mitochondrial dysfunction" would be the main cause of sarcoma progression, and evaluated antitumor effects of hypoxia improvements by the transcutaneous carbon dioxide (CO2) therapy on sarcomas. We revealed that iPS-related gene expression and mitochondrial dysfunction were associated with sarcoma progression, and that both of them were activated by hypoxic condition. In addition, transcutaneous CO2 therapy showed strong antitumor effects on sarcoma cells by decreased iPS-related gene expression and increased mitochondrial activity. The findings in this study strongly suggest that "Pluripotency" and "Mitochondrial dysfunction" should be the key of sarcoma progression, and that transcutaneous CO2 therapy can be an innovative therapeutic tool for sarcomas.

TOP